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Summary 
 
Persistent infections with oncogenic types of human papillomaviruses (HPVs) cause 
cervical and other anogenital carcinomas as well as cancers of the head and neck regions 
and thereby contribute significantly to the global cancer burden. Despite the existence of 
efficient prophylactic vaccines, the worldwide number of HPV-related cancer cases is 
estimated to rise. It therefore remains an important task to further investigate and 
delineate the molecular mechanisms that underlie HPV-driven tumorigenesis, in specific 
the actions of the two viral oncogenes E6 and E7 which promote and sustain the 
malignant phenotype of HPV-positive cancers. This is also hoped to offer new 
opportunities for HPV-targeted therapeutic intervention. 
In the present study, the two host cell genes FOXM1 and CKS1B were identified as novel 
target genes of HPV E6 and E7. Interestingly, both FOXM1 and CKS1 have been described 
to possess oncogenic properties in different types of cancers. By stimulating their 
transcriptional promoters, E6 and E7 increased FOXM1 and CKS1 mRNA and protein 
levels in HPV-positive cells. The inhibition of the tumor suppressor p53 and the pocket 
protein family by E6 and E7, respectively, was determined to mediate the activation of 
FOXM1 and CKS1B. Hence, the disruption of the repressive DREAM complex by E6/E7 
emerged as a likely mechanism involved in conveying HPV oncogene-induced promoter 
activation of FOXM1 and CKS1B. 
On the phenotypic level, the elevated level of CKS1 exerts pro-proliferative and 
senescence-suppressing effects in HPV-positive cancer cells. Furthermore, while not 
affecting proliferation per se, FOXM1 was shown to protect cervical cancer cells from the 
proliferation-suppressing effects of chemotherapy. In growth-arrested HPV-positive 
cells, neither FOXM1 nor CKS1 levels were found to decline, which would be in line with 
their activation by E6/E7 via DREAM disruption. 
Collectively, the results presented in this thesis contribute to a deeper understanding of 
HPV-driven carcinogenesis and decipher how the viral oncogenes E6 and E7 promote 
tumorigenesis through extensive modulation of the host cell’s molecular networks. They 
also provide evidence that interfering with FOXM1 or CKS1 expression or function could 
be an attractive future strategy for the therapy of HPV-induced cancers. 
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Zusammenfassung 
 
Persistierende Infektionen mit onkogenen Typen humaner Papillomviren (HPVs) sind 
Auslöser von Gebärmutterhalskrebs, anderen Krebsarten im Anogenitalbereich, sowie 
von bestimmten Kopf-Hals-Tumoren. Sie tragen damit wesentlich zur weltweiten 
Krebsinzidenz bei. Obwohl wirksame prophylaktische Impfstoffe verfügbar sind, wird 
erwartet, dass die Anzahl HPV-assoziierter Krebsfälle weltweit weiter steigen wird. Die 
Aufklärung der molekularen Mechanismen der HPV-induzierten Krebsentstehung bleibt 
daher weiterhin eine wichtige Aufgabe, insbesondere der Funktionen der viralen 
Onkogene E6 und E7, die für die Entstehung und Aufrechterhaltung des malignen 
Phänotyps HPV-positiver Tumorzellen entscheidend sind. Ein besseres Verständnis 
ihrer Wirkweise könnte auch zur Entwicklung innovativer, zielgerichteter 
Therapieoptionen gegen HPV-positive Tumore beitragen. 
In der vorliegenden Arbeit wurden die zwei Wirtszellgene FOXM1 und CKS1B als neue 
Zielgene von E6 und E7 identifiziert. Interessanterweise wird beiden Genprodukten 
onkogenes Potenzial in verschiedenen Krebsarten zugeschrieben. Die mRNA- und 
Proteinspiegel von FOXM1 und CKS1 werden durch E6 und E7 in HPV-positiven Zellen 
erhöht.  Dies erfolgt über eine transkriptionelle Aktivierung der FOXM1- und CKS1B-
Promotoren und wird durch die Hemmung des Tumorsuppressors p53 durch E6 und 
der Familie der „Pocket-Proteine“ durch E7 vermittelt. Dabei scheint die Interferenz mit 
dem transkriptionell repressiv wirkenden DREAM-Komplex Teil des Mechanismus zu 
sein, der zur Aktivierung der FOXM1- und CKS1B-Promotoren durch E6/E7 beiträgt. 
Phänotypisch tragen die erhöhten CKS1-Spiegel zur Proliferation von HPV-positiven 
Tumorzellen bei und unterdrücken das Auftreten von Seneszenz. Während ein direkter 
Effekt von FOXM1 auf das zelluläre Wachstum HPV-positiver Zellen nicht beobachtet 
wurde, schützt FOXM1 HPV-positive Tumorzellen gegenüber genoxtischen Agenzien wie 
Chemotherapeutika. In wachstumsarretierten HPV-positiven Zellen werden die Spiegel 
von FOXM1 und CKS1 nicht reduziert, was im Einklang mit der Theorie steht, dass die 
Aktivierung der beiden Gene durch eine E6/E7-abhängige Interferenz mit dem 
repressorischen DREAM-Komplex hervorgerufen werden kann. 
Diese Erkenntnisse tragen zu einem verbesserten Verständnis der HPV-induzierten 
Karzinogenese bei und erweitern den Wissenstand im Bezug auf die tiefgreifende 
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Modulation der molekularen Netzwerke der Wirtszelle durch E6 und E7. Sie zeigen 
außerdem auf, dass die Hemmung der Expression oder Funktion von FOXM1 und CKS1 
eine attraktive Strategie zur Behandlung HPV-positiver Tumore darstellen könnte.  
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1 Introduction 
 
1.1 Human papillomavirus (HPV) 
Members of the human papillomavirus family are small, non-enveloped double-stranded 
DNA viruses with a circular genome of about 8 kbp [1]. They infect mucosal and 
cutaneous surfaces via direct contact and belong to one of the most commonly 
transmitted infectious agents in humans. In fact, it is estimated that in the United States 
more than 80% of individuals have acquired at least one sexually-transmitted HPV 
infection by the age of 45 [2]. 
To date, more than 200 different HPV types are known, which are categorized into 
phylogenetic genera of which the alpha (mucosal tropism) and the beta genus 
(cutaneous tropism) are clinically most relevant and therefore best studied [3]. 
 
1.1.1 The HPV lifecycle 
Infection with HPV occurs via microlesions in the epithelial surface so that the virus can 
reach basal cells where it establishes an infection. HPV genome replication requires 
actively dividing cells which are normally only found in the lower layers of the 
epithelium [4]. 
Depending on the HPV type, the HPV genome consists of eight to ten open reading 
frames (ORFs) which are grouped into an early and a late region. Early genes (E) are 
required for genome replication and maintenance while the two late genes L1 and L2 
code for the viral capsid proteins [5]. E1 is a viral DNA helicase which together with the 
host cell replication machinery realizes viral genome amplification [6]. The E2 protein 
functions in transcriptional regulation and initiation of DNA replication [7]. E4 is 
predominantly expressed as an E1^E4 fusion protein and thought to contribute to 
genome amplification and virus synthesis and release [8]. The cellular activities of the 
transmembrane protein E5 are not entirely elucidated, however it has been implicated 
in modulating cellular signaling cascades and immune evasion [9] and is therefore 
regarded as potentially oncogenic [10]. The E6 and E7 proteins prevent cell cycle exit of 
the host cell during a productive infection since normally, after leaving the basal 
membrane to migrate to the epithelial surface, keratinocytes would start to differentiate 
and terminally end their replication. E6 and E7, however, inactivate proliferation-
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suppressing host cell proteins and thus drive continuing replication (see also 1.2.2). The 
HPV lifecycle is completed when the virus is assembled in the upper epithelial layer and 
shed from the epithelial surface [1].  
Initial and productive infections with HPV are most often cleared immunologically 
without causing apparent symptoms [11]. However, in some cases the viral genome can 
be maintained episomally at very low copy numbers in infected cells, a state called 
latency or persistent infection, from where it may be reactivated years to decades later 
[12]. 
 
 
1.2 HPV and cancer 
Harald zur Hausen and his group were the first to demonstrate the transforming 
potential of a persistent HPV infection and its role in the development of cervical cancer 
[13, 14]. Since then, it was established that so-called high-risk HPV types cause almost 
100% of cervical cancers and significant fractions of other anogenital cancers such as 
anal, vulvar or penile carcinomas [3]. In addition, a growing proportion of head and neck 
squamous cell carcinomas (HNSCC), especially of the oropharynx, are attributed to HPV. 
Carcinogenic (= high-risk) HPV types of the alpha genus include HPV16, -18, -31, -33, -
35, -39, -45, -52, -58 and -59 [3]. Besides, a contribution of beta-HPVs to non-melanoma 
skin cancer is discussed [15]. 
In total, more than 600000 new cancer cases per year are caused by infections with 
mucosal HPV types. This amounts to 4.5% of the global cancer incidence [16]. 
 
1.2.1 Pathogenesis of cervical cancer 
In rare cases, persistent infection with HPV can give rise to carcinomas through a multi-
step process which is mainly driven by the viral oncogenes E6 and E7. HPV-induced 
cervical carcinogenesis typically requires several decades from the first infection until 
the onset of cancer, during which an increasing number of mutations accumulate in the 
host cell. Therefore, cervical cancer is most often diagnosed in women beyond 45 years 
of age. 
At the uterine cervix, pre-cancerous lesions can be detected years before malignancy is 
established. They are termed cervical intraepithelial neoplasia (CIN) and are classified 
from grade 1 to 3 according to their increasing state of dedifferentiation and enhanced 
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risk of developing invasiveness [11]. Notably, most CIN1 lesions regress spontaneously 
and only very few cases progress to CIN2-3 and later to cancer (see figure 1). During the 
progression from CIN2 to CIN3, viral genome integration into the host chromosome can 
occur [17]. This is typically associated with the loss of many viral genes, while the 
oncogenes E6 and E7 are regularly retained [18]. The genome integration of oncogenic 
HPVs can result in further elevated E6 and E7 expression, however also lesions with 
episomally-maintained HPV genomes can be characterized by expressing increased E6 
and E7 levels during the progression of transformation [1]. 
 
Figure 1: Progression from a productive HPV infection to invasive cancer. In benign lesions, 
E6 and E7 are primarily expressed in the basal and parabasal epithelial layers to stimulate host 
cell proliferation throughout the differentiation programme. In surficial layers, E4 and late 
proteins are predominantly expressed to prepare virus assembly and shedding. However, during 
the progression to cancer, E6/E7 expression becomes more and more deregulated while the 
expression of other viral proteins is usually suppressed. Figure modified from [3]. 
 
1.2.2 Oncogenic properties of E6 and E7 
E6 and E7 are rather small viral proteins of ca. 150 and 100 amino acids, respectively, 
that produce and sustain the malignant phenotype of HPV-driven cancers. It has been 
shown that overexpression of E6/E7 is sufficient to cause immortalization of 
keratinocytes in vitro [19, 20] and E6/E7 suppression in cervical cancer cell lines leads 
to a rapid and efficient induction of senescence, an irreversible proliferative stop [21, 
22]. Hence, it was a central dogma that E6 and E7 are required to be expressed in 
cervical carcinoma cells at all times, making them so-called “oncogene-addicted”. 
Notably in recent years an exception emerged in tumor hypoxia, where low intratumoral 
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oxygen levels downregulate E6/E7 expression. Yet under this condition, the cells evade 
senescence and evoke a reversible state of cellular dormancy [23, 24, 25]. 
E6 and E7 are transcribed from a common promoter into a bicistronic mRNA which then 
yields either of the two gene products after a complex splicing process [26]. Both 
oncoproteins induce and support tumorigenesis through a variety of functions and 
interaction partners and together promote all of Hanahan’s and Weinberg’s ‘hallmarks 
of cancer’, being (I) sustaining proliferative signaling, (II) evading growth suppressors, 
(III) activating invasion and metastasis, (IV) enabling replicative immortality, 
(V) inducing angiogenesis and (VI) resisting apoptosis [27, 28]. 
E7’s primary function is attributed to the stimulation of host cell proliferation, mainly 
through its binding to the members of the pocket protein family, pRb, p130 and p107. 
This results in the displacement of other binding partners from the pocket proteins, such 
as the proliferation-inducing transcription factor E2F1 which is typically controlled 
through and inactivated by association with pRb [29]. This uncontrolled proliferation 
would usually result in the activation of checkpoint proteins such as p53 which then 
guide the cell towards apoptosis, a controlled form of cell death, or senescence, thereby 
eliminating it from the pool of proliferating cells. 
However, in HPV-positive cells, p53 is inactivated by the E6 oncoprotein: E6 interacts 
with the E3-ubiquitin ligase E6-AP and p53 to form a heterotrimer which enables the 
proteasomal degradation of p53 [30]. The induction of apoptosis or senescence is 
thereby efficiently suppressed. In addition, E6 proteins of the high-risk HPV types also 
contain a PDZ binding motif at their C-terminal end. Thus, in contrast to low-risk type E6 
proteins, they can modulate a multitude of cellular proteins containing PDZ domains 
which is also thought to contribute significantly to the transforming potential of E6 [31]. 
Other effects of E6/E7 expression include epigenetic alterations, changes in 
miRNA expression patterns and the induction of genomic instability [32, 33]. E6 and E7 
therefore cooperate to strongly enhance proliferation in HPV-positive cells while at the 
same time inactivating key tumor suppressor pathways (see figure 2). 
Introduction 
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Figure 2: The HPV oncoproteins E6 and E7 cooperate in tumorigenesis. Cellular 
proliferation is deregulated by the inhibition of pRb through E7. The aberrant cellular behaviour 
would normally lead to the induction of apoptosis (or senescence; not shown) by p53 
upregulation. However in the presence of E6, p53 is degraded leading to a blockage of apoptosis 
and thereby allowing the outgrowth of deregulated cells. Figure from [34]. 
 
1.2.3 Prevention and treatment of cervical cancer 
Due to the large time frame between the establishment of detectable forms of pre-cancer 
and the progression to carcinoma, monitoring and if necessary treatment of CIN lesions 
has proven high efficiency for the prevention of cervical cancer. Regular screening 
programs for women have been enabled and led to a drastic decrease in cervical cancer 
numbers in developed countries [35]. For decades, the Pap smear (named after its 
inventor George Papanicolaou) has been the gold standard for early detection of cervical 
lesions, but is now more and more replaced by the more accurate HPV DNA testing [36]. 
After the discovery of HPV as the causative agent for cervical cancer, prophylactic 
vaccines based on virus-like particles comprised of the L1 capsid protein have been 
developed. To date, three different formulations are available: Cervarix by 
GlaxoSmithKline protects against infection with HPV16 and -18 which together account 
for more than 70% of cervical carcinomas [37]. Gardasil (Merck) additionally confers 
protection against the two low-risk types HPV6 and -11 which are the main causes of 
genital warts [38]. A new nonavalent vaccine, Gardasil9 (Merck), additionally immunizes 
against infection with HPV31, -33, -45, -52 and -58 and is thereby hoped to prevent 
more than 90% of cancer-linked HPV infections [39]. 
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If prevention failed and cancer has arisen, surgical excision of the tumor and adjuvant 
radio- and chemotherapy is the primary choice of treatment. 
 
1.2.4 Why study additional HPV target genes? 
The existence of efficient prophylactic HPV vaccines makes cervical cancer a disease that 
is, in theory, completely preventable. Nevertheless, incidence rates of cervical and other 
HPV-associated cancers are estimated to continue to rise globally over the next years 
due to the increasing population worldwide [36]. Overall vaccination rates are low, even 
in industrialized nations, and low-income countries often lack the infrastructure to 
provide comprehensive vaccination and screening programs. Yet here, HPV prevalence 
in the population is particularly high [36]. Moreover, the existing vaccines are purely 
prophylactic and offer no profit for individuals who have already acquired a persistent 
infection. In the light of ca. 250000 deaths annually attributed to cervical cancer (in 
2012) the need for new therapeutic strategies against HPV-driven cancers remains high 
[3]. 
While E6/E7 would, in principle, represent ideal antigens for a therapeutic vaccination 
approach or other HPV oncogene-targeting therapies, so far no E6/E7-specific treatment 
has reached the market. The identification and characterization of novel downstream 
targets of E6/E7 should therefore not only result in a better understanding of HPV-
induced tumorigenesis but could also lead to the discovery of potential HPV-linked 
cellular vulnerabilities that might be exploited therapeutically.  
 
1.2.5 Transcriptome analyses for the identification of novel HPV targets 
In order to gain a deeper comprehension of HPV-driven carcinogenesis, Kuner et al have 
performed a transcriptome-based microarray in HPV18-positive HeLa cells, where 
E6/E7 had been knocked down by RNA interference (RNAi) [40]. Differentially regulated 
genes under these conditions possibly constitute cellular targets of the HPV oncogenes, 
since they react to changes in HPV oncogene expression. Upon E6/E7 knockdown, 648 
genes were found to be differentially expressed, of which 360 were downregulated and 
288 upregulated. 
FOXM1 and CKS1B are two cellular genes that showed a repression of 50% and 70% 
respectively at their mRNA expression levels, indicating that E6/E7 expression could be 
linked to the activation of both genes. This notion is of interest since both FOXM1 and 
CKS1B have been discussed before to possess oncogenic potential, making them 
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interesting putative targets for E6/E7 during HPV-induced carcinogenesis. Additionally, 
CKS1B expression was found to be stimulated by FOXM1 [41], positioning it as a 
potential downstream target of FOXM1 and thereby possibly connecting both genes in a 
common pathway. FOXM1 and CKS1B were therefore chosen as promising candidates for 
the study of novel HPV target genes and the cellular consequences of their modulation 
by E6/E7. 
 
 
1.3 The Forkhead Box Transcription Factor M1 – FOXM1 
FOXM1, also known as Trident, FKHL-16, MPP2 or HFH-11, is a member of the 
evolutionary conserved forkhead box family of transcription factors that all share 
similarities in their so-called ‘winged helix’ DNA binding domain [42]. FOXM1 is 
composed of a central DNA-binding domain, a strong C-terminal transactivation domain 
and a N-terminal autoinhibitory domain [43–45]. Differential splicing of the FOXM1 
mRNA gives rise to three isoforms, termed FOXM1a, -b and -c, of which FOXM1b and 
FOXM1c are transcriptionally active and FOXM1a is considered transcriptionally 
inactive [45, 46]. 
FOXM1 expression is regarded as being strictly proliferation-dependent [47]. Indeed, 
detectable levels of FOXM1 mRNA or protein are only found in embryonic or strongly 
proliferating adult tissues, but not in quiescent or terminally differentiated cells [48–50]. 
In addition, FOXM1 levels are extremely low in cells that have been arrested by serum 
starvation or undergone senescence [48, 51]. In proliferating cells, FOXM1 expression is 
cell cycle-dependent, with an upregulation of FOXM1 expression starting in late G1 
phase and peaking at the G2/M phase transition [52]. The same dynamic is described for 
FOXM1 activity which results from increasing multi-site phosphorylation during 
progression of the cell cycle, thereby relieving repression of the transactivation domain 
by the FOXM1 autoinhibitory domain [53–55]. 
While some research groups have proposed the existence of a FOXM1 autoregulatory 
loop by which FOXM1 induces and potentiates its own transcription [56, 57], others 
could not verify this proposition [58]. It is however well established that FOXM1 levels 
are transcriptionally repressed by p53 and activated by E2F1 after its release from pRb 
[59–63]. These observations are in line with FOXM1’s central role in the cell 
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cycle-dependent MuvB-B-Myb-FOXM1 complex (MMB-FOXM1) to activate timely 
transcription of G2/M phase genes [64]. 
FOXM1 was found indispensable for embryonic development, since FOXM1-/- knockout 
mice die before birth with severe developmental defects in heart, liver and lung [52, 65, 
66]. FOXM1 knockdown in primary mouse embryonic fibroblasts (MEFs) resulted in 
heavy polyploidy, delayed entry into mitosis and disturbed chromosome segregation 
[67]. These results underline the essential role for FOXM1 in coordinating cell cycle 
progression, specifically of the G2/M phase transition. 
 
1.3.1 FOXM1 in cancer 
Highly elevated levels of FOXM1 transcript and protein have been found in tumors 
originating from many different tissues, including a. o. breast, liver, pancreatic, 
colorectal, lung, head and neck and cervical cancers [68]. High FOXM1 levels frequently 
correlate with a more severe course of disease, advanced tumor stage and a significantly 
worsened clinical prognosis [69]. While all three splice variants were shown to be 
equally upregulated in cancer, a differential contribution of single isoforms to the 
oncogenic phenotype is discussed, however with inconsistent results [58, 70, 71]. 
Overall, FOXM1 is one of the most commonly overexpressed genes across different 
human tumor entities [72]. Correspondingly, it forms part of the CIN25 gene signature 
that predicts outcome for multiple cancer types based on the expression of 25 genes 
related to chromosomal instability and of the ‘cervical cancer proliferation cluster’ for 
the prediction of early progression of cervical carcinomas [73, 74]. In some reports, an 
‘addiction’ of proliferating tumor cells to FOXM1 is postulated [75, 76]. 
FOXM1 exerts its tumorigenic properties via the modulation of a multitude of cellular 
processes. Being under the control of two tumor suppressors that are frequently 
mutated or otherwise inactivated in cancers, p53 and pRb, regulation of FOXM1 is 
usually aberrant in transformed cells. Mutant p53 was found to elevate FOXM1 
expression, in contrast to its wildtype counterpart which has a repressive effect on the 
FOXM1 promoter [77, 78]. Apart from its general proliferation-promoting effect, FOXM1 
also further deregulates cellular proliferation, for example via activation of the oncogene 
MYC [79, 80]. Moreover, many components of the DNA damage repair (DDR) machinery 
are reported FOXM1 targets, resulting in enhanced DDR which can increase resistance to 
apoptosis, for example in response to treatment with chemotherapeutic agents [59, 81–
84]. Furthermore, FOXM1 is described to potentially confer replicative immortality by 
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the suppression of senescence and thus stem cell-like properties to FOXM1-
overexpressing cells [51, 85]. The vascular endothelial growth factor (VEGF) is another 
FOXM1 target gene, linking FOXM1 to the stimulation of angiogenesis [86, 87]. In 
addition, high FOXM1 expression was found to increase invasion and metastasis and 
promote epithelial-mesenchymal transition, for instance via upregulation of the matrix 
metalloproteinases MMP2 and -9 [88, 89]. Thus, similar to the HPV oncogenes, FOXM1 
also promotes all hallmarks of cancer and can be regarded as a bona fide cellular 
oncogene [90].  
A tumor-promoting role for FOXM1 has also been discussed in the pathogenesis of 
cervical cancer: Modulation of FOXM1 levels by the HPV oncogenes has been reported, 
with different modes of action observed: Lüscher-Firzlaff et al proposed a direct 
interaction between HPV16 E7 and FOXM1 which increases transactivational activity of 
FOXM1 [91] while Jaiswal et al report a stabilization of FOXM1 protein levels by E7 
expression, due to the inhibition of FOXM1 SUMOylation through E7 [92]. In contrast, 
two other publications show an activation of FOXM1 by E6, but not E7, in oral 
keratinocytes [93, 94]. Interestingly, cellular FOXM1 levels increase strongly from 
normal cervical epithelium over CIN lesions to squamous cell carcinoma [95]. 
 
 
1.4 The cyclin-dependent kinases regulatory subunit 1B –CKS1 
The family of CKS proteins is evolutionary highly conserved in eukaryotes and 
recognized as an important regulator of orderly cell cycle progression. Its first member 
was identified in the fission yeast Schizosaccharomyces pombe and termed Suc1 
(suppressor of cdc2) [96]. In humans two orthologues, CKS1 (gene name: CKS1B) and 
CKS2, have been identified that both are 79 amino acids long and share a sequence 
homology of 81% [97]. Although they have been found to substitute for each other in 
murine knockout studies [98], they nevertheless also have additional independent 
functions [99]. 
Both CKS proteins were found to bind tightly to cyclin-dependent kinases (CDKs) and 
are thought to stimulate their activities. However, the exact mechanism of CDK 
modulation by CKS proteins in mammals remains elusive. CKS1 and CKS2 are 
indispensable for proper cell cycle progression [100], as can also be seen from CKS1B-/- 
CKS2-/- double knockout mice which die very early during embryogenesis [98]. CKS 
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mRNA and protein levels start to rise in late G1 with a first peak before the entry into S 
phase. A second peak occurs at the transition from G2 to M phase [97, 101].  
In addition, CKS1 interacts with the F-Box-protein Skp2 in the Skp1-Cullin1-F-box 
protein (SCF) ubiquitin ligase complex. This SCFSkp2 complex requires CKS1 as an 
adaptor protein to bind and ubiquitinate its targets, the most prominent being the cell 
cycle inhibitor p27 [102, 103]. This leads to the proteasomal degradation of 
ubiquitinated p27 at the G1/S phase transition and therefore timely progression of the 
cell cycle. Other ubiquitination targets of SCFSkp2-CKS1 include p21 and p130 [104, 105] 
which both have important functions in cell cycle regulation as well. This role of CKS1 is 
not shared by CKS2.  
A CKS1-/- knockout does not lead to lethality in mice, although they have a smaller body 
size that is attributed to reduced cell division as a result of p27 accumulation [103]. 
Mouse embryonic fibroblasts devoid of CKS1 also show a lower proliferation and 
undergo premature senescence [103]. But also p27-independent functions of CKS1 
during cell cycle regulation have been demonstrated [106]. Additionally, regulatory 
roles of CKS1 as a transcriptional activator and in growth signaling have also been 
discussed [107, 108]. 
 
1.4.1 CKS1B as a potential proto-oncogene 
CKS1B transcript and protein levels are elevated in many human cancers, such as gastric, 
colorectal, hepatocellular, breast, bladder and oral squamous cell carcinomas a. o. [109].  
This overexpression is generally linked to a worse prognosis which is attributed to 
CKS1’s proliferation-promoting effects [110]. CKS1B is therefore discussed as a cellular 
proto-oncogene which when deregulated contributes to tumorigenesis [111, 112]. 
CKS1B knockdown inhibits proliferation and induces apoptosis in cell lines derived from 
lung, breast and liver cancers [112, 113, 114]. Vice versa, elevated levels of CKS1 lead to 
failure of the intra-S-phase checkpoint in response to replication stress, which could 
support the expansion of (pre-)malignant cells [115]. This may pose a potential 
therapeutic vulnerability of CKS1-overexpressing cancer cells, as a selective 
sensitization to DNA damaging agents that induce replication stress (such as 
5-fluorouracil or methotrexate) was demonstrated [116, 117]. 
It is not well understood what causes the elevated CKS1 expression in different types of 
cancers. An increase of CKS1B promoter activity has been shown in response to the MYC 
oncogene in B-cell lymphoma in mice, although the promoter lacks a recognized Myc 
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binding site [118]. Upregulation of CKS1B by the FOXM1 transcription factor and a 
repressive effect of p53 have been reported as well [41, 101]. 
 
 
1.5 Research Objectives 
Despite considerable advances in the fields of prevention and treatment of HPV-
associated cancers, there remains an urgent need for a better understanding of the 
molecular mechanisms of HPV-driven carcinogenesis. A previous transcriptome analysis 
raised the possibility that FOXM1 and CKS1B may represent new cancer-linked cellular 
targets for activation by the HPV oncogenes. 
 
This study therefore aims at 
 
(I) validating whether and how FOXM1 and CKS1B are modulated by the E6/E7 
oncoproteins. E6/E7 knockdown and overexpression studies in cervical 
cancer cells and immortalized keratinocytes will be conducted and the 
resulting effects on FOXM1 and CKS1B expression will be assessed. 
(II) analyzing a possible transcriptional regulation of the FOXM1 and CKS1B 
promoters by the HPV oncogenes, using luciferase reporter constructs.  
(III) elucidating if FOXM1 and CKS1 are situated downstream of one another in 
cervical cancer cells or whether they constitute independent target genes of 
HPV. 
(IV) characterizing the phenotypic effects of FOXM1 and CKS1 activation in 
cervical cancer cells. This will include knockdown studies followed by 
proliferation and cell death assays, such as cell cycle analyses, senescence 
assays, apoptosis detection, colony formation assays and live-cell imaging. In 
addition, a special focus will be laid upon the cellular effects of FOXM1 
modulation under conditions of DNA damage. 
 
Overall, the present study aims to elucidate the underlying mechanisms and 
functional consequences of the E6/E7-linked elevation of FOXM1 and CKS1 
expression in HPV-positive tumor cells. This should improve our concepts of the 
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molecular mechanisms of HPV-induced carcinogenesis and may pave the way for 
new therapeutic options. 
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2 Results 
 
2.1 FOXM1 and CKS1B as new candidate target genes of HPV 
A transcriptome array identified FOXM1 and CKS1B as new candidate target genes of the 
HPV oncoproteins in cervical cancer since they exhibited significantly repressed mRNA 
levels as a response to E6/E7 knockdown in HeLa cells [40]. This would suggest that 
FOXM1 and CKS1B are upregulated upon E6/E7 expression in HPV-positive cancer cells. 
 
2.1.1 FOXM1 and CKS1 are downregulated upon E6/E7 knockdown 
First, I aimed at validating the results from the microarray by independent experimental 
assays. E6 and E6/E7 knockdowns using siRNAs in three different HPV-positive cervical 
cancer cell lines were performed and FOXM1 and CKS1 expression was evaluated at the 
protein and the mRNA level. 
E6 and E7 are derived from a common transcript and their mRNA is subjected to a 
complex splicing process before yielding the respective gene products. While 
conjunctive knockdown of E6/E7 or knockdown of E6 alone have been achieved, so far it 
has been technically not feasible to specifically knock down E7 alone [119, 120]. 
Conclusions concerning the effects of E7 silencing alone may therefore only be indirectly 
drawn from a combination of experiments conducting E6 and E6/E7 knockdowns and 
therefore need to be interpreted with some caution. 
As shown in figure 3A, depletion of E6/E7 by RNAi caused a strong downregulation of 
FOXM1 and CKS1 protein levels in both HPV18-positive HeLa and HPV16-positive SiHa 
cells, as detected by immunoblot analyses. On the contrary, FOXM1 and CKS1 levels 
were not affected by E6 knockdown alone in HeLa cells and only showed a slight 
reduction in SiHa cells under these conditions. These results were mirrored on the 
mRNA level, as seen in RT-qPCR experiments (fig. 3B). Successful repression of E6 or 
E6/E7 was verified by specific antibodies and the reconstitution of p53 (fig. 3A) and on 
the RNA level by the use of specific primer pairs for E6 or E6/E7 transcripts (fig. 3B).  
 
By use of the HeLa “p53 null” cell line which stably expresses an shRNA against p53 
[121] and efficiently silences the TP53 gene (fig. 3A), a requirement for p53 
reconstitution to mediate FOXM1 or CKS1 downregulation could be precluded: FOXM1 
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or CKS1 protein and RNA levels in the TP53 knockdown cell line reacted with the same 
expression patterns as HeLa cells in which TP53 was not silenced (fig. 3A, B). 
 
Figure 3: FOXM1 and CKS1 levels are upregulated by E6/E7 expression. A, B: HeLa, HeLa 
“p53 null” and SiHa cells were treated with siRNAs against E6 or E6/E7. Protein levels were 
determined by Western blot analyses (A). Relative mRNA expression of E6/E7, E6, FOXM1 and 
CKS1B was determined using RT-qPCR; shown is the log10 of the mean expression relative to 
siContr-1 (=0; not depicted) with standard deviations of 3 independent experiments (B). 
siContr-1: control siRNA. C: Stably transduced NOK cells were analysed for their protein levels 
by Western blot. Vinculin: loading control. 
 
2.1.2 E6/E7 increase expression of FOXM1 and CKS1 in keratinocytes 
If FOXM1 and CKS1B are indeed target genes of E6/E7 and are repressed by E6/E7 
silencing, then ectopic expression of E6/E7 in HPV-negative cells should result in 
upregulation of the two genes. To that end, human telomerase reverse transcriptase 
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(hTERT)-immortalized normal oral keratinocytes (NOKs), which had been stably 
transduced with HPV16E6/E7, were analysed for their FOXM1 and CKS1 protein levels. 
This model system is of particular interest and significance, since mucosal keratinocytes 
constitute the primary host cells for high-risk HPV infection [122]. As recognizable from 
figure 3C, FOXM1 and CKS1 levels were clearly increased after expression of HPV16 E6 
and E7 in NOKs. This observation further supports the assumption that FOXM1 and 
CKS1B represent novel target genes of HPVE6/E7 and are activated by the viral 
oncogenes. 
 
 
2.2 FOXM1 and CKS1 are transcriptional targets of E6 and E7 
2.2.1 The FOXM1 promoter is activated by E6 and E7 
To further analyse the effect of E6 and E7 expression on FOXM1, luciferase reporter 
assays were conducted in order to assess a possible effect on the FOXM1 transcriptional 
reporter. Two promoter constructs of FOXM1 have been tested, the 2.4 kbp full-length 
promoter termed pGL3-FOXM1long, and a shorter, ca. 300 bp variant named 
pGL3-FOXM1 (fig. 4A). Both reporters showed considerable activity over the pGL3 basic 
backbone, with pGL3-FOXM1 being much stronger activated (to ca. 100-fold) than 
pGL3-FOXM1long, which might be due to the existence of potential negative regulatory 
elements in the longer fragment.  
Next, the reporter constructs were employed for E6 and E6/E7 knockdown experiments 
in HeLa to test for their transcriptional activity upon viral oncogene repression. 
Mirroring the effects on protein and mRNA level presented in figure 3, the pGL3-FOXM1 
promoter construct showed a strong decline in promoter activity after E6/E7 
knockdown, while it was unaffected by E6 knockdown alone (fig. 4B). A similar tendency 
was observed using pGL3-FOXM1long as reporter, however the effects were weaker, 
potentially due to the much lower basal promoter activation of the construct. Therefore, 
pGL3-FOXM1 was chosen as FOXM1 promoter construct for further experiments. Also, 
previous analyses by Korver et al had demonstrated that the pGL3-FOXM1 promoter 
fragment retains inducibility during cell cycle progression, just as pGL3-FOXM1long, and 
may therefore be regarded as containing the essential promoter regions of FOXM1 [42]. 
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Figure 4: The FOXM1 promoter is responsive to activation by E6 and E7. A: Schematic 
representation of the two promoter constructs pGL3-FOXM1 and pGL3-FOXM1long and their 
basal expression levels in HeLa in luciferase reporter assays; control for normalization: pGL3 
basic. B: Luciferase reporter assays of pGL3-FOXM1 and pGL3-FOXM1long in HeLa co-
transfected with pSUPER-shContr-1, pSUPER-sh18E6 or pSUPER-sh18E6/E7; control for 
normalization: pGL3-FOXM1 or pGL3-FOXM1long + pSUPER-shContr-1. shContr-1: control 
shRNA. C: Luciferase reporter assays of pGL3-FOXM1 in MCF-7 co-transfected with pBCH-16E6 
and/or   pCMV-16E7-HA/flag;   control   for   normalization:   (continued   on   next   page) 
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Having shown that the FOXM1 promoter is responsive to E6/E7 knockdown, 
overexpression experiments of E6 and E7 in HPV-negative cells were performed next. To 
that end, MCF-7 breast cancer cells were chosen, because they are wildtype for p53 and 
no mutations in either of the three pocket proteins pRb, p130 and p107, the main 
downstream targets of E7, have been described [123]. pGL3-FOXM1 was significantly 
activated by ectopic expression of 16E6, 16E7 or both oncogenes in MCF-7 cells (fig. 4C). 
Interestingly, whereas the activity of the FOXM1 promoter was not affected by 
knockdown experiments specifically targeting E6 (fig. 4B), ectopic E6 expression alone 
was sufficient to activate the FOXM1 promoter.  The combined overexpression of E6 and 
E7 yielded an over-additive activation in comparison to the single oncoproteins. 
 
In order to elucidate which intracellular pathways mediate promoter activation by E6, a 
shRNA against p53 was employed. Knockdown of TP53 led to a similar activation as 
overexpression of E6 in MCF-7 (fig. 4D), arguing for a repressive effect of p53 on the 
FOXM1 promoter which is relieved by the introduction of E6. Notably, concomitant 
silencing of TP53 and expression of E6 resulted in significantly higher FOXM1 promoter 
activation in comparison to the single constructs. The p53CONLuc reporter was used to 
verify successful downregulation of p53 (fig. 4D). This plasmid carries a p53 consensus 
binding site upstream of the luciferase gene [124]. Also here, simultaneous expression of  
 
(Figure legend to fig. 4 continued) pGL3-FOXM1 + pCMV-HA/flag + pBCH. D: Luciferase reporter 
assays of pGL3-FOXM1 or pGUP.PA.8-p53CONLuc in MCF-7 co-transfected with pBCH-16E6 
and/or pSUPER-shp53; control for normalization: pGL3-FOXM1 or pGUP.PA.8-p53CONLuc + 
pSUPER-shContr-1 + pBCH. shContr-1: control shRNA. E, left panel: Luciferase reporter assays 
of pBL-FOXM1, p21Luc or pGUP.PA.8-p53CONLuc in H1299 co-transfected with pCMVtk-p53; 
control for normalization: pBL-FOXM1, p21Luc or pGUP.PA.8-p53CONLuc + pCMVtk. E, right 
panel: Luciferase reporter assays of pBL-FOXM1 in H1299 co-transfected with pBCH-16E6 or 
pCMV-16E7-HA/flag; control for normalization: pBL-FOXM1 + pBCH or pCMV-16E7-HA/flag. F: 
Luciferase reporter assays of pGL3-FOXM1 in MCF-7 co-transfected with pCMV-16E7-HA/flag, 
pCMV-16E7ΔDLYC-HA/flag or pCMV-E2F1; control for normalization: pGL3-FOXM1 + pCMV-
HA/flag. Western blot of 16E7 overexpression in MCF-7, γ-tubulin: loading control. G: Luciferase 
reporter assays of pBL-FOXM1 in 5637 co-transfected with pCMV-16E7-HA/flag or pCMV-
16E7ΔDLYC-HA/flag; control for normalization: pBL-FOXM1 + pCMV-HA/flag. Given is the log10 
of the mean RLUs (relative luciferase units) relative to the respective control (=0; usually not 
depicted). Error bars represent standard deviations. Asterisks indicate statistically significant 
differences to the respective control as determined by one-way ANOVA (***p < 0.001, **p < 0.01, 
*p < 0.05). 
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shp53 and E6 decreased activity of p53CONLuc more efficiently than either construct 
alone, indicating that the cellular p53 level was further decreased by the double 
transfection. 
 
The p53-negative non-small cell lung cancer (NSCLC) cell line H1299 was used to further 
characterize the effect of p53 expression on the FOXM1 transcriptional region. This cell 
line carries a homozygous partial deletion of TP53 and does not express any p53 protein 
[125]. Since, for unknown reasons, the pGL3 basic backbone was found to respond 
considerably to p53 in overexpression experiments in H1299 cells, the FOXM1 promoter 
construct was cloned into the pBL backbone [126] which is much less p53-responsive 
(data not shown), yielding pBL-FOXM1. Overexpression of p53 in H1299 cells inhibited 
pBL-FOXM1 activity, further strengthening the notion that the FOXM1 promoter can be 
repressed by p53 (fig. 4E). Under the same experimental conditions, two positive 
controls for p53-mediated transactivation, the p53-responsive reporter constructs 
p21Luc and p53CONLuc were highly upregulated. The absence of p53 in H1299 was also 
linked to the inability of 16E6 to activate pBL-FOXM1, while the activating effect of 16E7 
was preserved (fig. 4E). Collectively, these data indicate that the E6 oncoprotein is able 
to activate transcription of the FOXM1 gene by inducing the degradation of p53, whereby 
p53’s repressive effect on the FOXM1 promoter is alleviated. 
 
The E7 oncoprotein sequesters pocket proteins like pRb or p130, thereby preventing 
them to bind to their targets, where they usually have inhibitory effects. Notably, FOXM1 
promoter activation by E7 in MCF-7 cells was abrogated when the pocket protein-  
binding-deficient mutant 16E7ΔDLYC was expressed instead of wildtype 16E7 (fig. 4F). 
To exclude that decreased FOXM1 promoter stimulation by 16E7ΔDLYC was due to a 
lower expression level of the mutant, protein expression of 16E7 and 16E7ΔDLYC was 
assessed by Western blot. 
A main target of pRb is the pro-proliferative transcription factor E2F1 [29]. Expression 
of E7 typically leads to an activation of E2F1 target genes, because E2F1 is released from 
pRb when the pocket protein is bound by E7. Indeed, the FOXM1 promoter was found 
responsive to overexpression of E2F1 (fig. 4F). However, also pocket proteins other than 
pRb appear able to mediate FOXM1 promoter activation via E7: In the pRb-negative 
bladder cancer cell line 5637, increased activity of the reporter construct was still 
conferred by E7 expression and appeared to require the ability to bind to pocket 
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proteins, since FOXM1 promoter activation was abrogated upon mutation of the pocket 
protein binding domain of E7 (fig. 4G). 
 
In conclusion, the FOXM1 promoter was shown to be responsive to activation by the HPV 
oncogenes E6 and E7. Activation by E6 is hereby likely mediated by inducing the 
degradation of p53, which mitigates the repressive effect of p53 on the FOXM1 
transcriptional promoter. While the pRb-E2F1 axis certainly plays a role in inducing 
FOXM1 transcriptional activity via E7, also the interference with the function of the other 
pocket proteins, p130 and p107, can mediate E7-induced promoter activation. 
 
2.2.2 The CKS1B promoter is activated by E6 and E7 
To analyse the regulation of the CKS1B promoter, a 550 bp fragment upstream of the 
CKS1B transcription start site was cloned from HeLa genomic DNA into the pBL reporter 
plasmid, thereby obtaining pBL-CKS1B. (The detailed cloning strategy is delineated in 
Materials & Methods, section 4.4.3.) pBL-CKS1B was tested for its activity in HeLa and 
yielded luciferase values 100-200 times above the pBL basic vector (data not shown). 
As depicted in figure 5A, pBL-CKS1B was significantly inhibited after E6/E7 knockdown, 
while E6 knockdown led to a slight but insignificant upregulation of the promoter 
activity. Vice versa, pBL-CKS1B was stimulated by overexpression of 16E6, 16E7 or both 
in MCF-7 (fig. 5B). Collectively, these data indicate that the HPV oncogenes can activate 
the CKS1B promoter. Concurrent expression of E6 and E7 resulted in an additive effect 
on promoter activation (fig. 5B). 
 
Upregulation of pBL-CKS1B by E6 was mimicked by knockdown of TP53 (fig. 5C), 
indicating the p53 downregulation leads to the stimulation of the CKS1B promoter. 
Concomitant expression of E6 and shp53 resulted in significantly higher luciferase 
values of the pBL-CKS1B construct than E6 or shp53 expression alone. Interestingly, and 
in contrast to the FOXM1 promoter, the CKS1B promoter remained inducible by E6 
overexpression in the absence of p53 in H1299 cells (please compare fig. 5D and fig. 4E). 
These findings suggest that the E6-mediated activation of CKS1B expression is not 
necessarily only induced via p53 downregulation, which could be a cell-line specific 
effect. However, degradation of p53 by E6 still has an activating effect on pBL-CKS1B 
(fig. 5C). 
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Figure 5: The transcriptional promoter of CKS1B is activated by E6 and E7. A: Luciferase 
reporter assays of pBL-CKS1B in HeLa co-transfected with pSUPER-sh18E6 or pSUPER-
sh18E6/E7; control for normalization: pBL-CKS1B + pSUPER-shContr-1. shContr-1: control 
shRNA. B: Luciferase reporter assays of pBL-CKS1B in MCF-7 co-transfected with pBCH-16E6 
and/or pCMV-16E7-HA/flag; control for normalization: pBL-CKS1B + pBCH + pCMV-HA/flag. C: 
Luciferase reporter assays of pBL-CKS1B in MCF-7 co-transfected with pBCH 16E6 and/or 
pSUPER-shp53; control for normalization: pBL-CKS1B + pBCH + pSUPER-shContr-1. shContr-1: 
control shRNA. D: Luciferase reporter assays of pBL-CKS1B in H1299 co-transfected with pBCH-
16E6 or pCMV-16E7-HA/flag; control for normalization: pBL-CKS1B + pBCH or pCMV-HA/flag. 
E: Luciferase reporter assays of pBL-CKS1B in MCF-7 co-transfected with pCMV-16E7-HA/flag 
or pCMV-16E7ΔDLYC-HA/flag; control for normalization: pBL-CKS1B + pCMV-HA/flag. For 
equivalent expression of 16E7 and 16E7ΔDLYC, see fig. 4F. F: Luciferase reporter assays of pBL-
CKS1B in MCF-7 or H1299 co-transfected with 10 or 50 ng pCMV-E2F1; control for 
normalization: pBL-CKS1B + pCMV-HA/flag. G: Luciferase reporter assays of pBL-CKS1B in 5637 
co-transfected with pCMV-16E7-HA/flag or pCMV-16E7ΔDLYC-HA/flag; control for 
normalization: pBL-CKS1B + pCMV-HA/flag. Given is the log10 of the mean RLUs (relative 
luciferase units) relative to the respective control (=0; not depicted). Error bars represent 
standard deviations. Asterisks indicate statistically significant differences to the respective 
control as determined by one-way ANOVA (***p < 0.001, **p < 0.01, *p < 0.05). 
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CKS1B promoter activation via E7 likely depends on pocket protein binding as the 
pocket protein binding mutant 16E7ΔDLYC failed to stimulate the CKS1B promoter 
(fig. 5E). Unlike the FOXM1 promoter however, the CSK1B promoter was not responsive 
to E2F1 expression (fig. 5F). This was tested in MCF-7 and H1299 cells and by using 
different amounts of the E2F1 overexpression plasmid, including the conditions that had 
conferred activation of the FOXM1 promoter construct (fig. 4F). The pRb-E2F1 axis 
therefore apparently does not mediate promoter activation of CKS1B by E7. In line with 
this notion, the CKS1B promoter was also activated by E7 in the pRb-deficient cell line 
5637. Yet, this process still appears to depend on the pocket protein binding capacity of 
E7 since the CKS1B promoter activation was abrogated upon mutation of the pocket 
protein binding domain in E7 (fig. 5G).  
 
Recapitulating, the HPV oncoproteins E6 and E7 confer promoter activation of CKS1B. 
While activation by E6 occurs via p53-dependent and potentially also –independent 
functions thereof, activation by E7 is mediated by binding to the pocket proteins p130 
and p107 and probably does not require the pRb-E2F1 axis. 
 
These findings also offer a possible explanation why a downregulation of FOXM1 and 
CKS1 was not observed in HPV-positive cell lines after E6 knockdown alone (see fig. 3), 
while overexpression of only E6 was capable of activating both the FOXM1 and the 
CKS1B promoter in HPV-negative cells: Since E7 levels remain largely unchanged after a 
specific E6 knockdown, the activating stimulus exerted by E7 is preserved and may 
superimpose the effect of E6 silencing. 
 
 
2.3 CKS1 expression regulation by E6/E7 is independent of FOXM1 
Several reports describe CKS1B as a downstream target gene activated by FOXM1, 
usually based on the observation that CKS1B mRNA was found to decline after FOXM1 
depletion [41, 57, 127]. To investigate this possible connection, siRNAs against FOXM1 
and CKS1 were employed. Potent downregulation of the respective targets was achieved 
on protein and transcript level (fig. 6A and B). Expectedly, while silencing of CKS1B 
resulted in an accumulation of its degrading target p27, FOXM1 levels stayed unaffected 
(fig. 6A). Vice versa neither CKS1B mRNA nor protein expression was altered by FOXM1 
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knockdown. Also the p27 protein level remained unchanged after FOXM1 depletion. A 
weak but significant downregulation of CKS1B promoter activity was observed after 
FOXM1 knockdown in reporter assays (fig. 6C), but this effect was not mirrored by 
changes at the endogenous CKS1 mRNA or protein level. Furthermore, silencing of 
FOXM1 did not impair CKS1B promoter stimulation by E6 and E7 overexpression in 
MCF-7 cells (fig. 6C). Collectively, these data indicate that FOXM1 is dispensable for the 
activation of the CKS1B promoter by the HPV oncogenes. The CKS1 expression level in 
HPV-positive cancer cells therefore seems to mainly depend on E6/E7 expression, 
independent of FOXM1. This notion is further corroborated by the different mechanisms 
of promoter activation by E6/E7 for FOXM1 and CKS1B unravelled in the preceding 
experiments. 
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Figure 6: CKS1B and FOXM1 are independently regulated target genes of E6/E7. A, B: 
Western blot (A) or RT-qPCR (B) of FOXM1 or CKS1B knockdown by siRNAs in HeLa. Actin: 
loading control. Shown is the log10 of the mean expression relative to siContr-1 (=0) with 
standard deviations of 2 (FOXM1 mRNA)/3 (CKS1B mRNA) independent experiments. siContr-1: 
control siRNA. C, left panel: Luciferase reporter assays of pBL-CKS1B in HeLa co-transfected 
with pSUPER-shFOXM1-2/3 (=shFOXM1); control for normalization: pBL-CKS1B + pSUPER-
shContr-1. C, middle panel: Luciferase reporter assays of pBL-CKS1B in MCF-7 co-transfected 
with pBCH-16E6 and/or pSUPER-shFOXM1-2/3 (= shFOXM1); control for normalization: pBL-
CKS1B + pBCH + pSUPER-shContr-1. C, right panel: Luciferase reporter assays of pBL-CKS1B in 
MCF-7 co-transfected with pCMV-16E7-HA/flag and/or pSUPER-shFOXM1-2/3 (=shFOXM1); 
control for normalization: pBL-CKS1B + pCMV-HA/flag + pSUPER-shContr-1. Given is the log10 of 
the mean RLUs (relative luciferase units) relative to the respective control (=0; not depicted). 
shContr-1: control shRNA. Error bars represent standard deviations. Asterisks indicate 
statistically significant differences to the respective control as determined by one-way ANOVA 
(***p < 0.001, *p < 0.05). 
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2.4 CKS1 is required for cell cycle progression and senescence 
suppression   in HPV-positive cells 
Since cellular CKS1 and FOXM1 levels are increased by E6/E7 expression, it is of high 
interest to study the impact of this upregulation in cervical cancer cells and to identify 
whether and how this contributes to their malignant phenotype. 
To investigate the effects of CKS1 upregulation by E6/E7, the cellular phenotype after 
CKS1B knockdown was characterized. To that end, three different shRNAs were 
employed independently to minimize the risk of studying off-target effects. All three 
shRNAs shCKS1_1, -_2 and -_3 efficiently downregulated CKS1 expression on protein and 
RNA level and expectedly resulted in the upregulation of the p27 cell cycle inhibitor 
(fig. 7A). Accordingly, knockdown of CKS1B accumulated HeLa cells at the G1/S phase 
transition in the cell cycle, with cells in G1 phase increasing from 53.2% in control cells 
to up to 79.1% in shCKS1-treated cells (fig. 7B). In addition, the number of senescent 
cells increased in CKS1-depleted cells, as verified by the positive staining of the well-
established senescence marker senescence-associated β-galactosidase (SA β-Gal) 
(fig. 7C). 
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Figure 7: CKS1B knockdown in HeLa leads to cell cycle arrest and senescence induction. A: 
Western blot (left) and RT-qPCR (right) analyses of HeLa cells after CKS1B knockdown. 
γ-tubulin: loading control. Shown is the log10 of the mean expression relative to shContr-1 (=0) 
with standard deviations of 3 independent experiments. B: Cell cycle analyses of HeLa cells after 
CKS1B knockdown. Cell cycle phase distributions are given in %. C: SA β-Gal assay of HeLa cells 
after CKS1B knockdown. Split ratios: 1:10 for shContr-1; 1:5 for shCKS1_1, -_2, and -_3. 
shContr-1: control shRNA. 
 
The same phenotype was observed in SiHa cells using siRNA-mediated CKS1B 
knockdown: CKS1-depleted cells showed a cell cycle arrest at the G1/S phase transition 
(fig. 8A) which resulted in the efficient induction of senescence, as indicated in figure 8B. 
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Figure 8: CKS1B knockdown in SiHa leads to cell cycle arrest and senescence induction. A: 
Cell cycle analyses of SiHa cells after CKS1B knockdown. Cell cycle phase distributions are given 
in %. B: SA β-Gal assay of SiHa cells after CKS1B knockdown. Split ratios: 1:10 for siContr-1; 1:5 
for siCKS1. A, B: Shown is one representative replicate of 2 independent experiments. siContr-1: 
control siRNA. 
 
The diminished proliferative capacity after CKS1B knockdown was also confirmed in 
colony formation assays (CFAs). Here, cells were subjected to CKS1B knockdown over a 
longer time period. Episomal maintenance of the shRNA expression vector (pCEP4sh) 
targeting CKS1B was ensured by selection with the antibiotic hygromycin B (HYG). 
CKS1B knockdown in each HeLa, SiHa and CaSki cells resulted in a strongly decreased 
number of outgrowing colonies, indicative of impaired colony formation capacity in 
comparison to control transfected cells (fig. 9). 
In conclusion, cervical cancer cells require CKS1 for cell cycle progression, a failure of 
which leads to a cell cycle arrest in the G1 phase and the induction of senescence. Thus, 
the increase of CKS1B expression induced by E6/E7 has pro-proliferative and 
senescence-suppressing potential in HPV-positive cancer cells, thereby providing a 
growth advantage.  
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Figure 9: CKS1B knockdown decreases colony formation capacity. HeLa, SiHa and CaSki 
cells were subjected to CKS1B knockdown and proliferation was monitored in CFAs. HYG 
concentration: HeLa 200 µg/mL; SiHa 250 µg/mL; CaSki 100 µg/mL. Shown is one 
representative replicate of 2 independent experiments. shNeg: control shRNA. 
 
 
2.5 FOXM1 is required for DNA damage repair in HPV-positive cells 
2.5.1 Proliferation of cervical cancer cells is not impaired by FOXM1 knockdown 
Next, the possible consequences of FOXM1 upregulation by E6/E7 were studied in HeLa 
cells using three different shRNAs for FOXM1 downregulation.  
Efficient downregulation of FOXM1 by shFOXM1_1, -_2, and -_3 was achieved on the 
protein and transcript level (fig. 10A). However, neither alterations in cell cycle 
distribution (fig. 10B), nor the induction of senescence (fig. 10C) or apoptosis (fig. 10D) 
could be detected. Corresponding results were obtained in SiHa cells (see supplemental 
figure 1 in the appendix). These data indicate that the proliferation of cervical cancer 
cells is unaffected by FOXM1 downregulation. 
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Figure 10: Characterization of the cellular phenotype after FOXM1 knockdown in HeLa. A: 
Western blot (left) and RT-qPCR (right) analyses of HeLa cells after FOXM1 knockdown. 
γ-tubulin: loading control. Shown is the log10 of the mean expression relative to shContr-1 (=0) 
with standard deviations of 2 independent experiments. B: Cell cycle analyses of HeLa cells after 
FOXM1 knockdown. Cell cycle phase distributions are given in %. C: SA β-Gal assay of HeLa cells 
after FOXM1 knockdown. Split ratio: 1:10. D: TUNEL staining in HeLa cells after FOXM1 
knockdown. Scale bar: 50 µm. B-D: Shown is one representative replicate of 2 independent 
experiments. shContr-1: control shRNA, siContr-1: control siRNA. 
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In order to monitor cellular proliferation after FOXM1 knockdown more closely over a 
prolonged time period and in multiple cell lines, the IncuCyte Live-Cell Analysis System 
was utilized. For a more accurate evaluation, stably transfected cell lines with the red 
fluorescent protein mCherry tagged to histone 2B (termed “mCherry H2B”) were used 
when available. Use of these cell lines allows for the calculation of actual cell numbers 
(as each cell carries a red fluorescent nucleus) in contrast to the customary 
interpretation of confluency percentages by the analysis software. 
As can be recognized from figure 11A, cellular proliferation remained unchanged by 
FOXM1 knockdown in HeLa mCherry H2B and CaSki mCherry H2B cells. Image 
acquisition was started 24 h after transfection and typically carried on over an 
observation period of 100-120 h. This time frame widely exceeds the usual evaluation 
point 72 h post transfection for knockdown experiments. The maintained 
downregulation of FOXM1 by siRNA for 120 h post transfection was verified in 
immunoblots for HeLa, HeLa “p53 null” and CaSki cells (see supplemental figure 2 in the 
appendix). 
To validate whether the residual p53 in cervical cancer cells plays a role in the cellular 
response to FOXM1 depletion, the HeLa “p53 null” cell line was also employed for 
analyses in the live-cell imaging system. Here, an interesting observation was made: 
Whether or not FOXM1 knockdown affected proliferation in HeLa “p53 null” depended 
on whether the stock culture had been grown in medium containing the antibiotic G418 
the week before experiments were conducted (fig. 11B). In specific, the stock culture of 
this cell line is usually kept under selection with G418 to ensure stable expression of the 
shRNA against p53. During experiments, the antibiotic is omitted from the cell culture 
medium. However, HeLa “p53 null” cells that came freshly from the G418-containing 
medium and were seeded for experiments in G418-free medium, displayed a growth 
disadvantage when FOXM1 was knocked down in comparison to control siRNA-treated 
cells (fig. 11B, right panel). In contrast, if the stock culture had been kept in G418-free 
medium for at least one week before experiments were started, no difference in 
proliferation by FOXM1 knockdown was observed (fig. 11B, left panel), just as in HeLa 
mCherry H2B and CaSki mCherry H2B. Maintained downregulation of p53 in cells 
cultured without G418 selection was monitored by immunoblot, shown in figure 11C. 
Also, no significant effect of G418 on basal FOXM1 levels was observed. 
As demonstrated by the experiments presented in figures 10 and 11, FOXM1 is 
obviously dispensable for proliferation in cervical cancer cells. This effect is independent 
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of p53. These findings are in notable contrast to the literature where FOXM1 is generally 
regarded as an inducer of proliferation in a variety of cell types including cervical cancer 
[95, 128–130]. 
 
Figure 11: Proliferation of cervical cancer cell lines is unaffected by FOXM1 knockdown. A: 
Proliferation of HeLa mCherry H2B and CaSki mCherry H2B was monitored after FOXM1 
knockdown in the IncuCyte Live-Cell Analysis System. B: Proliferation of HeLa “p53 null” that 
had been cultured without (left) or with (right) G418 in their stock culture medium, was 
monitored after FOXM1 knockdown in the IncuCyte Live-Cell Analysis System. Data produced 
jointly with Julia Botta. A, B: Image acquisition was started 24 h after transfection. siContr-1: 
control siRNA. C: Immunoblot analysis verifying the maintained downregulation of p53 in HeLa 
“p53 null” cultured without G418 for 3 weeks. Data produced jointly with Julia Botta. γ-tubulin: 
loading control. 
 
CFAs are another way of studying the proliferative capacity of cells over a longer period 
of time (typically 1.5 – 3 weeks from transfection to colony fixation). Although the 
growth curves of HeLa and CaSki cells had demonstrated no inhibitory effect of FOXM1 
downregulation on their proliferation, the number of colonies outgrowing in the CFA 
was markedly reduced (fig. 12). SiHa cells on the other hand, showed no reduced colony 
formation capacity after FOXM1 silencing. 
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Figure 12: FOXM1 knockdown decreases colony formation capacity in HeLa and CaSki. 
HeLa, CaSki and SiHa cells were subjected to FOXM1 knockdown and proliferation was 
monitored in CFAs. HYG concentration is given in the figure. Shown is one representative 
replicate of 2 independent experiments. shNeg: control shRNA. 
 
These CFAs are carried out in the presence of HYG, an antibiotic that inhibits protein 
biosynthesis in pro- and eukaryotes [131], to select for plasmid maintenance and 
therefore stable shRNA expression. As has been observed before for G418 in the HeLa 
“p53 null” cells, decreased colony formation capacity after FOXM1 knockdown could 
therefore possibly be linked to HYG selection. 
 
Both HYG and G418 are mainly known and used for their antibiotic properties, caused 
by inhibition of protein translation. However, there are indications in the literature that 
both substances could also induce DNA damage in treated cells [132, 133]. Even though 
G418 was removed from the medium before experiments were started, long-term 
cultivation with the compound could have possibly resulted in an accumulation of DNA 
damage lesions. Could the growth-inhibitory effect of FOXM1 knockdown under these 
conditions be the consequence of DNA damage? 
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2.5.2 FOXM1 knockdown sensitizes cervical cancer cells to DNA damage 
To test the above-mentioned hypothesis, HPV-positive cells were subjected to FOXM1 
knockdown and concomitant treatment with different DNA damaging agents (including 
HYG) and proliferation was monitored in the IncuCyte Live-Cell Analysis System over 
several days. Camptothecin (CPT), doxorubicin (DOX) and cisplatin (cis-
diamminedichloridoplatinum, CDDP) are all clinically relevant chemotherapeutics that 
induce DNA damage via different modes of action: CPT is an inhibitor of topoisomerase I 
by covalently binding to the enzyme, DOX intercalates with DNA and thereby inhibits 
topoisomerase II and CDDP forms intrastrand bulky adducts at the DNA. CDDP is a first-
line chemotherapeutic in the treatment of cervical cancers and topotecan and irinotecan, 
two derivatives of CPT, are also approved for cervical cancer therapy. 
Figure 13 shows growth curves of HeLa, HeLa “p53 null” and CaSki cells after 
knockdown of FOXM1 and concomitant treatment with HYG, CPT, DOX or CDDP. In all 
cases, while FOXM1-depleted cells proliferated at the same rate as control cells if 
untreated, a growth reduction after treatment with DNA damaging agents was observed. 
Low, sub-lethal doses of the drugs were chosen to enable largely unaffected 
proliferation of control cells in contrast to FOXM1 knockdown cells. The challenge with 
DNA damaging agents was therefore shown to selectively target FOXM1-depleted cells 
and impair their proliferation. These observations may explain why HeLa and CaSki cells 
showed reduced colony outgrowth after FOXM1 knockdown in CFAs performed under 
HYG selection and why HeLa “p53 null” cells that came freshly from G418-containing 
medium are sensitive to FOXM1 depletion. 
The presented results point to a significant involvement of FOXM1 in the DNA damage 
response (DDR) of HPV-positive cancer cells. A contribution of p53 to this regulation 
appears unlikely, since the “p53 null” HeLa cells are equally affected as HeLa cells that 
express p53. These findings are also of potential clinical interest since they indicate that 
the E6/E7-induced increase in FOXM1 expression may contribute to the resistance of 
HPV-positive cancer cells towards genotoxic chemotherapy.  
Results 
37 
 
Figure 13: DNA damaging agents selectively impair proliferation of FOXM1 knockdown 
cells. HeLa (A), HeLa “p53 null” (B) and CaSki (C) were transfected with siFOXM1 or siContr-1 
and treated with different DNA damaging agents at the indicated concentrations. Data 
acquisition was performed with the IncuCyte Live-Cell Analysis System and started with the 
addition of the drugs 24 h after transfection. HeLa “p53 null” cells had been cultivated without 
G418 for at least one week before the start of experiments. siContr-1: control siRNA. B: Data 
produced jointly with Julia Botta. 
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Interestingly, while this phenomenon applied consistently to the three cell lines 
described in figure 13, no increased sensitivity to DNA damaging agents was noticed in 
FOXM1-depleted SiHa cells (fig. 14). This observation is in line with the results from the 
CFA, where FOXM1 knockdown under HYG selection also did not impair colony 
formation capacity in SiHa cells. The role of FOXM1 knockdown in mediating sensitivity 
to DNA damaging agents therefore seems to be influenced by cell-type specific 
differences. 
 
Figure 14: Proliferation of SiHa cells is not affected by FOXM1 knockdown under DNA 
damage. SiHa were transfected with siFOXM1 or siContr-1 and treated with different DNA 
damaging agents at the indicated concentrations. Data acquisition was performed with the 
IncuCyte Live-Cell Analysis System and started with the addition of the drugs 24 h after 
transfection. Shown is one representative replicate of 2 independent experiments. siContr-1: 
control siRNA. 
 
In order to verify that treatment with the different compounds indeed led to an 
accumulation of DNA damage lesions in FOXM1-silenced cells, immunofluorescent 
staining for the DNA damage marker γ-H2AX was performed. Phosphorylation of the 
histone 2AX at Ser139 (yielding γ-H2AX) is a very sensitive marker for the detection of 
double-strand breaks (DSBs) in the DNA [134]. With the use of a phospho-specific 
antibody in immunofluorescence, distinct γ-H2AX foci can be detected, indicative of DNA 
damage sites. 
Figure 15 shows a clear increase of γ-H2AX signal in FOXM1 knockdown HeLa cells 
treated with 10 nM CPT or 10 nM DOX for 48 h in comparison to control cells. The 
dosages employed were the same as for the proliferation studies. FOXM1 knockdown per 
se did not induce accumulation of the DNA damage marker. 
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Figure 15: γ-H2AX foci accumulate in FOXM1 knockdown cells after DNA damage 
treatment. HeLa were subjected to FOXM1 knockdown and treated with 10 nM CPT or 10 nM 
DOX 24 h after the transfection, for 48 h. Cells were stained for γ-H2AX and DAPI by 
immunofluorescence.siContr-1: control siRNA. 
 
Thus, FOXM1 can enhance resistance of cervical cancer cells to genotoxic agents. While 
proliferation itself is unaffected by FOXM1 depletion, cells lacking FOXM1 fail to 
effectively repair DSBs caused by different means of DNA damage. The accumulation of 
DNA lesions is likely the cause for impaired proliferation of FOXM1 knockdown cells 
after treatment with low doses of chemotherapeutics. 
 
 
2.6 FOXM1 in proliferative arrest 
FOXM1 is generally regarded as being a strictly proliferation-dependent transcription 
factor [48, 49, 135]. To test whether FOXM1 repression after E6/E7 knockdown is rather 
a secondary effect due to the proliferative halt induced by E6/E7 silencing in HPV-
positive cancer cells, it was of interest to see how FOXM1 levels react to a proliferation 
arrest in HPV-positive cells under conditions of continuous E6 and E7 expression. 
The compound hydroxyurea (HU) was employed to achieve efficient cell cycle arrest 
under conditions where viral oncoprotein expression levels remained unaltered. HU is 
an inhibitor of the enzyme ribonucleotide reductase that supplies the cellular 
deoxyribonucleoside triphosphate (dNTP) pool by catalysing the conversion of 
ribonucleoside diphosphates (NDPs) to deoxyribonucleoside diphosphates (dNDPs). HU 
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treatment therefore leads to depletion of the dNTP pool and typically arrests cells at the 
G1/S border of the cell cycle. 
HeLa and SiHa cells were treated with 1 mM HU for 48 h. Interestingly, the proliferation 
arrest induced by HU did not decrease FOXM1 (or CKS1) levels in either HeLa or SiHa 
cells (fig. 16A, B). Rather, FOXM1 protein levels were increased in both cell lines. At the 
same time, E7 levels stayed unaltered by the treatment. (In general, E6 protein levels 
were not found to react differently from E7 and were therefore not always probed in the 
Western blots.) Effective cell cycle arrest under HU treatment was verified by EdU 
assays and assessment of cell cycle profiles (fig. 16A, B). HU-treated HeLa cells did not 
incorporate any EdU any more over the 2 h-incubation period, indicative of an efficient 
cell cycle arrest. The cell cycle profile showed a clear decrease of cells in G2 phase which 
led to increases in G1 and S phase. While the majority of cells was arrested in G1 phase, 
some have entered S phase were they failed to complete DNA replication due to the 
missing dNTPs. 
In contrast, quite a high proportion of SiHa cells (48.7%) were found EdU-positive in 
comparison to 18.6% in unarrested cells. However, the distribution of cells in the dot 
plot and the cell cycle profile varied widely between HU-treated and untreated SiHa 
cells. Apparently after HU treatment, most cells have still entered the S phase and 
started DNA replication which they failed to complete because the dNTP pool was 
depleted. Upon addition of EdU, cells which are already stuck in the S phase were 
therefore still capable of incorporating the thymidine analogue and turn weakly EdU-
positive. The cell cycle profile corroborates an S phase arrest by HU in SiHa cells. 
In conclusion, HeLa and SiHa cells were arrested after treatment with 1 mM HU, yet in 
both cell lines, CKS1 and FOXM1 levels were not reduced or even upregulated. This is in 
contrast to the notion that FOXM1 expression is thought to be strictly proliferation-
dependent. To receive a better understanding of the responses of FOXM1 and CKS1 to 
cell cycle arrest and whether these depend on E6/E7 expression, HeLa and SiHa cells 
were arrested by the means of additional anti-proliferative agents: Mimosine is a non-
proteinogenic amino acid that induces cell cycle arrest in the late G1 phase. Excess of the 
nucleotide thymidine also inhibits the activity of ribonucleotide reductase, arresting 
cells at the G1/S phase transition or during S phase [136]. Nocodazole is a microtubule 
polymerization inhibitor and therefore prevents cells from completing mitosis. Efficient 
blocking of cell cycle progression with these compounds in HeLa cells under the given 
experimental conditions has been shown by Leitz et al [137]. 
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Figure 16: FOXM1 and CKS1 expression is not proliferation-dependent. A, B: HeLa (A) and 
SiHa (B) were treated with 1 mM HU for 48 h and then harvested for protein extraction or EdU 
assay. For EdU assay, one representative replicate of 2 independent experiments is shown. C, D: 
Immunoblots of HeLa (C) or SiHa (D) cells treated with 400 µM mimosine, 2 mM thymidine, 
0.04 µg/mL nocodazole or the respective solvent control for 24 h (HeLa) or 48 h (SiHa). 
γ-tubulin, Actin: loading controls. 
 
After incubation with the different cell cycle inhibitors, FOXM1 levels were not 
decreased but rather increased, at least slightly, in all treatments for HeLa and SiHa cells 
(fig. 16C, D). CKS1 levels remained largely unchanged, with the exception of mimosine 
treatment in SiHa cells, were they were found to decline. This latter effect was 
accompanied by a downregulation of E7 by this treatment. Under all other experimental 
conditions, HPV18 or -16 E7 levels were not affected by the arrest. Hence, the 
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experiments with the different anti-proliferative agents collectively support the notion 
that in HPV-positive cancer cell lines, sustained expression of FOXM1 and CKS1 is not 
dependent on actively proliferating cells. This effect was largely conserved regardless of 
the cell cycle inhibitor chosen for treatment.  
It was noted that during cell cycle-inhibiting treatments, the higher molecular weight 
species in the band pattern of the FOXM1 antibody signal accumulated to a greater 
degree. While the identity of the different bands produced in Western blot for FOXM1 is 
not ultimately resolved, they could potentially result from different post-translational 
modifications such as phosphorylations a. o. [138].  
Is the unexpected upregulation of FOXM1 expression in proliferation arrest a 
phenomenon specific to HPV-positive or other tumor cells? To answer this question, HU 
treatment was performed on HPV-positive cervical cancer cell lines as well as on HPV-
negative cell lines from other cancer entities and primary fibroblasts. A range of 
different dosages and treatment periods was analysed. Figure 17A shows that FOXM1 
expression was elevated in HPV-positive cells after HU treatment, also at higher doses of 
HU or longer treatment periods in comparison to figure 16. This phenomenon appears 
to be p53-independent as shown by analysis of the HeLa “p53 null” cells. In contrast, 
FOXM1 levels in the primary fibroblasts Fib101 and CxF6 clearly decreased after 
prolonged proliferative arrest (fig. 17B). Concordantly, also HPV-negative MCF-7 and 
H1299 cancer cell lines showed a decline in FOXM1 protein levels. That the effect of 
increased FOXM1 levels after proliferation arrest is however not necessarily a HPV-
dependent phenomenon, is demonstrated by the HPV-negative bladder cancer cell line 
5637 which also exhibits FOXM1 elevation after HU treatment. It is however tempting to 
speculate whether the genomic RB1 deletion of 5637 cells mimics the downstream 
effects of E7 expression and therefore contributes to FOXM1 upregulation. 
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Figure 17: The effects of HU treatment on FOXM1 levels in HPV-positive and -negative 
cells. A: HeLa, HeLa “p53 null” and SiHa cells were treated daily with the indicated 
concentrations of HU and harvested after 24, 48 or 72 h. B: Fib101 and CxF6 primary fibroblasts, 
MCF-7, H1299 and 5637 tumor cell lines were treated daily with the indicated concentrations of 
HU and harvested after 48 or 72 h. γ-tubulin: loading control. 
 
Collectively, these data indicate that while cell cycle arrest by HU treatment resulted in a 
downregulation of FOXM1 in many HPV-negative cells, this effect could not be observed 
in the HPV-positive cell lines investigated here, where FOXM1 protein levels were rather 
upregulated after HU treatment. 
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3 Discussion 
 
HPV-induced cancers depend on the expression of the viral oncogenes E6 and E7 for the 
establishment and maintenance of their malignant phenotype. E6 and E7 are known to 
exert their oncogenic functions via the modulation of various host cell pathways which 
are however not entirely recognized yet. The identification and characterization of novel 
HPV target genes is therefore of interest to achieve a deeper understanding of HPV-
induced host cell transformation down to the molecular mechanisms and may 
additionally identify new therapeutic options for HPV-positive cancers. Thus within the 
scope of this project, the activation of the transcription factor FOXM1 and the cell cycle 
regulator CKS1 by the HPV oncogenes was investigated in cervical cancer cells with 
regard to the underlying regulatory mechanisms and phenotypic consequences. 
 
 
3.1 FOXM1 and CKS1 are novel target genes of HPV E6 and E7 
In the present studies, E6/E7 knockdown experiments revealed that FOXM1 and CKS1 
mRNA and protein levels were strongly downregulated after E6/E7 repression in 
different HPV16- and HPV18-positive cervical cancer cells. Mechanistic studies indicate 
that these regulatory phenomena were independent of the reconstitution of p53 and not 
detected if only E6 was depleted. In further support of the notion that FOXM1 and CKS1B 
represent novel target genes of the HPV oncogenes, overexpression of E6/E7 in NOK 
cells upregulated protein levels of FOXM1 and CKS1. 
Collectively, these results imply that FOXM1 and CKS1B are activated by E6/E7 
expression. In line with this notion, elevated levels of FOXM1 and CKS1 have been found 
in cervical carcinomas – which are virtually always HPV-positive – in comparison to 
healthy cervical tissue [95, 139]. Furthermore, levels of p27, which is degraded by CKS1, 
decrease in CIN lesions during the progression to malignancy [140–142]. 
Downregulation of FOXM1 by silencing of E7, but not of E6, has been reported in SiHa 
cells and cell lines from other HPV-positive cancers [93]. Notably however, and other 
than implied by the authors, the siRNA sequences provided for E7 knockdown in this 
publication target a region in the common E6/E7 transcript, meaning they will repress 
both E6 and E7 expression [119]. Downregulation of FOXM1 after treatment with these 
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siRNAs is therefore likely a result of simultaneous E6/E7 repression and thus 
corroborates the results obtained in this study. 
 
3.1.1 Activation of the FOXM1 promoter by E6/E7 
Luciferase reporter assays indicated that the activation of the FOXM1 gene takes place, 
at least in part, at the level of its transcriptional promoter. In general, activity of the 
FOXM1 promoter mirrored the regulation of FOXM1 mRNA and protein expression, in 
that the downregulation or overexpression of E6 and E7 results in its repression or 
activation, respectively. This further supports the hypothesis of an activation of FOXM1 
by the HPV oncogenes. As was observed on the mRNA and protein level, E6 knockdown 
alone had no effect on promoter activity in HeLa. On the contrary, overexpression of E6 
in HPV-negative MCF-7 cells activated the FOXM1 promoter also in the absence of E7. 
Furthermore, the over-additive effect of concomitant E6 and E7 expression on the 
FOXM1 promoter speaks for a cooperation of the two oncogenes in the activation of 
FOXM1.  
The stimulation of the FOXM1 promoter is likely to be mediated by well-characterized 
target pathways downstream of E6/E7: A repressive effect of p53 on the FOXM1 
promoter was detected, which is alleviated by E6-mediated degradation of p53. This 
finding is in line with previous reports describing an upregulation of FOXM1 mRNA, 
protein and promoter activity after p53 downregulation [59–61]. The stimulatory effect 
of E7 on the FOXM1 promoter appears to be mediated via the transactivating function of 
the transcription factor E2F1, which is released after E7 sequesters its binding partner 
pRb. Consistently, a pocket protein binding-deficient 16E7 mutant failed to stimulate the 
FOXM1 promoter. In line with this idea, two E2F1 binding sites have been described 
previously in the FOXM1 promoter close to the transcriptional start site [59]. However, 
also in the absence of pRb, pocket protein-mediated stimulation of the FOXM1 promoter 
by E7 seems to occur, raising the possibility of an additional pRb-independent 
mechanism of FOXM1 promoter activation by p130 and/or p107. 
 
These observations fit into a model where the viral oncogenes cooperate in promoting 
proliferation and tumorigenesis in their host cells by perturbation of the so-called 
DREAM (DP, Rb-like, E2F4 and MuvB) complex via the modulation of p53 and pocket 
proteins [143]. DREAM is a transcriptionally repressive complex that silences 
unscheduled expression of cell cycle genes and therefore prevents premature entry into 
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the cell cycle in quiescent cells [144]. The pocket protein p130 (in rare cases substituted 
by p107) constitutes an integral part of this multi-protein complex. It has been 
demonstrated that the sequestration of p130 by E7 leads to the disruption of DREAM 
[145, 146]. Besides, the maintenance of DREAM is promoted by the p53 target p21 
[147]. Hence, E6-induced degradation of p53 further facilitates the disassembly of 
DREAM [148]. An overview of the cooperating actions of E6 and E7 in promoting cell 
cycle progression by the prevention of DREAM complex formation is presented in 
figure 18. 
 
Figure 18: HPV E6 and E7 perturb formation of the repressive DREAM complex and drive 
proliferation. E7 sequesters the pocket protein p130 or p107, thereby disturbing DREAM and 
alleviating transcriptional repression. By mediating degradation of p53, E6 promotes the 
accumulation of the inactivated hyperphosphorylated form of p130/p107 due to inhibition of 
the p53-p21 axis, which also results in DREAM disruption. Furthermore, the formation of the 
activating MuvB-B-Myb-FOXM1 (MMB-FOXM1) complex is promoted. Figure adapted from 
[143]. 
 
This concept is further supported by a report which demonstrates that FOXM1 is a target 
of DREAM-mediated repression [143]. Consistently, the FOXM1 promoter contains a 
CHR (cell cycle homologous region) element, one of the main binding motifs for DREAM 
[149]. Therefore, disruption of DREAM by E6 and E7 likely stimulates FOXM1 
expression, in addition to the activating effect of the pRb-E2F1 axis which is also induced 
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by E7. Vice versa, knockdown of E6/E7 in HPV-positive cells leads to a reassembly of 
DREAM and sequestration of E2F1, resulting in repression of the FOXM1 promoter and 
subsequent downregulation of its mRNA and protein levels. This model would also 
explain why depletion of E6 alone is not sufficient to repress FOXM1, since expression 
levels of the E7 oncoprotein are preserved during E6 knockdown. In fact, disruption of 
DREAM assembly by E7 has been shown to also occur independently of E6 [143] which 
in addition would also account for the fact that reconstitution of p53 was found to be 
dispensable for FOXM1 silencing after E6/E7 knockdown. 
  
3.1.2 Activation of the CKS1B promoter by E6/E7 
To date, little is known about the structure and regulatory elements of the human CKS1B 
promoter and a possible regulation of CKS1 by the HPV oncogenes has not been 
reported so far. 
The results of the present work support the notion that CKS1B expression is activated by 
the HPV oncogenes. This is indicated by the downregulation of CKS1 protein levels as 
well as of CKS1B mRNA amounts and promoter activity after E6/E7 knockdown. 
Moreover, CKS1B promoter activity was found to be induced after expression of HPV E6 
and/or E7 in HPV-negative MCF-7 cells. Consistent with being stimulated by HPVs, 
CKS1B expression was found to be upregulated in early stage cervical carcinomas in 
comparison to normal cervical epithelium [139]. 
Mechanistically, E7-mediated activation of CKS1B likely depends on pocket protein 
interaction, since the effect was lost upon mutation of the E7 domain that mediates the 
interaction with pRb, p107 and p130. However, in contrast to the FOXM1 promoter, the 
CKS1B promoter does not carry recognized E2F1 binding sites and could not be 
activated by ectopic E2F1 expression. Consequently, pRb was found dispensable for 
CKS1B activation by experiments performed in pRb-negative 5637 cells. Nevertheless, 
judging from the inability of the pocket protein-binding E7 mutant to activate the CKS1B 
promoter also in these cells, the other pocket proteins p130 and p107 are likely to 
mediate E7-induced CKS1B promoter stimulation. As for FOXM1, the interference with 
DREAM complex formation by the HPV oncogenes therefore seems a plausible 
mechanism for CKS1B upregulation. Indeed, CKS1B has been described as DREAM target 
and carries a CHR regulatory element in its promoter [101, 143].  
Activation of the CKS1B promoter was also demonstrated to occur after expression of 
HPV E6. This was, at least in part, linked to the decrease in p53 levels, arguing for a 
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repressive effect of p53 on CKS1B transcription which is presumably conveyed via 
DREAM complex retention [147]. Repression of CKS1B promoter activity by p53 is 
supported by the literature [101]. Interestingly however, E6 also induced activation of 
CKS1B in H1299 cells in the absence of p53. This speaks for a possible p53-independent 
component in the stimulation of CKS1B by E6, a notion which is also supported by the 
significant increase of promoter activity after concomitant overexpression of E6 and 
shp53 in MCF-7 cells in comparison to the single expression of E6 or shp53. 
p53-independent functions of E6 are known [150] and described to occur via different 
modes of action. For example, the PDZ-binding motif of high-risk HPV E6 mediates 
proteasomal degradation of Dlg, MAGI and Scribble proteins which are important factors 
in cell polarity [31]. The activation of telomerase (hTERT) by E6 which is an important 
step in cell immortalization was also demonstrated to occur independent of p53 
degradation [151]. Protein-protein interactions between E6 and paxillin, E6-binding 
protein (E6-BP) and Creb-binding protein (CBP)/p300 have been described [152, 153]. 
Also the activation of transcriptional promoters by E6 independent of p53 is known, 
such as for the promoters of VEGF and the oncogene MYC [154, 155]. Interestingly, Myc 
has also been described to activate transcription of CKS1B [118, 156]. Thus, Myc could 
be the link how E6 upregulates CKS1B promoter activity independent of p53. Moreover, 
for none of the other p53-independent E6 targets a connection to CKS1B regulation has 
been reported so far. 
Transcriptional regulation by E6 independent of p53 remains however a very unusual 
phenomenon. Since the promoter activation of CKS1B by E6 in the absence of p53 was so 
far only investigated in the H1299 cell line, the results require further investigation and 
until then should be interpreted with caution. 
 
3.1.3 Crosstalk between FOXM1 and E6/E7 in regulating CKS1B expression 
CKS1B is generally considered as a downstream target of FOXM1 in the literature. This 
notion is based on FOXM1 knockdown studies in U2OS osteosarcoma cells and MEFs that 
show downregulation of CKS1B transcripts as well as of other cell cycle genes of the 
G2/M phase after FOXM1 depletion [41]. The presence of a CHR element in the CKS1B 
promoter and its peak expression at the G2/M transition in the cell cycle are in line with 
CKS1B being a transcriptional target of FOXM1 [101, 157]. 
However, after knockdown of FOXM1 in HeLa cells, no reduction of CKS1 mRNA or 
protein levels was observed. Accordingly, also no upregulation of p27 was detected, 
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unlike after CKS1B knockdown. Nevertheless, CKS1B promoter activity showed a weak 
but significant downregulation after FOXM1 repression in HeLa. While FOXM1 therefore 
seems to be able to stimulate CKS1B transcriptional activity in HPV-positive cells, the 
activating effect of E6 and E7 on the promoter appears to be much stronger than of 
FOXM1. This could explain why no effect of FOXM1 knockdown was observed at the 
CKS1 mRNA and protein level while E6/E7 were expressed. Moreover, FOXM1 
expression was found to be dispensable for CKS1B promoter activation by the HPV 
oncogenes. These results warrant the conclusion that FOXM1 and CKS1B constitute 
independent target genes of E6/E7. This is also supported by the different pathways for 
promoter activation elucidated and described in this thesis. In addition, different 
phenotypic outcomes of FOXM1 and CKS1B knockdowns were observed in cervical 
cancer cells (see section 3.2), further arguing against a relevant upstream/downstream 
relationship between FOXM1 and CKS1 in HPV-positive cells. 
 
Overall, FOXM1 and CKS1B were identified as novel host cell target genes of both HPV 
oncogenes E6 and E7. Upregulation of FOXM1 and CKS1 occurs via their transcriptional 
promoters and translates on to the mRNA and protein level. It was therefore of further 
interest to study the phenotypic effects of elevated CKS1 and FOXM1 levels on cervical 
cancer cells. 
 
 
3.2 Phenotypic consequences of CKS1 and FOXM1 activation in cervical 
cancer cells 
3.2.1 CKS1 is required for cell cycle progression and senescence suppression in      
HPV-positive cancer cells 
To characterize the consequences of CKS1B activation by the HPV oncogenes, 
knockdown studies of CKS1B were conducted in HPV-positive HeLa and SiHa cells. 
Depletion of CKS1 resulted in a proliferative arrest in the G1 phase of the cell cycle and 
in senescence induction. On the long term, cell cycle arrest and senescence induction 
resulted in a clearly diminished outgrowth of colonies in CFAs. 
Accumulation of the cell cycle inhibitor p27 was caused by CKS1B knockdown, and in 
fact the observed effects of CKS1 repression may be largely explained by elevated levels 
of p27: Cell cycle arrest at the G1/S boundary has been described to be caused by 
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upregulation of p27 in HeLa [158, 159]. In addition, the prolonged upregulation of cell 
cycle inhibitors such as p27 and p21 can result in the induction of senescence [160]. 
While CKS1 has additional functions apart from the degradation of p27, presumably 
through the activation of cyclin-dependent kinases (CDKs), their nature is not well 
characterized in humans [106, 109]. Whether p27-independent functions of CKS1 
contribute to the observed phenotype in HPV-positive cells, is therefore difficult to 
assess. 
Whereas these considerations may explain the induction of senescence upon CKS1B 
silencing, in the literature apoptosis rather than senescence induction in response to 
CKS1B knockdown has been described for different cancer cell lines from lung, breast 
and liver [112–114]. In addition, Martinsson-Ahlzen et al report apoptosis induction in 
HeLa cells after double knockdown of CKS1 and CKS2, although experimental data is not 
provided by the authors [98]. HPV-positive cells are considered to be protected from 
apoptosis due to E6-mediated degradation of p53. Theoretically, the failure of HPV-
positive cells to upregulate p53 in response to the cell cycle arrest caused by CKS1 
depletion could therefore explain why no apoptosis was observed under the 
experimental conditions here. Since cells are however arrested at the G1/S border of the 
cell cycle for a prolonged time, subsequent senescence induction may follow. 
 
Overall, elevated levels of CKS1 in HPV-positive cells are likely to play an important role 
in ensuring continuous proliferation of the tumor cells. In addition, by facilitating 
orderly cell cycle progression, CKS1 may support HPV-positive cells in the evasion from 
senescence, e.g. via induction of p27 degradation. 
These properties of CKS1 expression could therefore offer the potential for therapeutic 
exploitation, for instance by the application of inhibitors that interfere with CKS1 
function. Indeed, experimental evidence links the anti-tumorigenic effects of different 
compounds to CKS1 inhibition: Oncostatin M is a member of the interleukin-6 family of 
cytokines which showed a broad anti-proliferative effect in glioblastoma cells. This was 
attributed to upregulation of p21 and p27 which was in part mediated by suppression of 
CKS1 and its partner substrate receptor Skp2 [161]. Vorinostat is a histone deacetylase 
inhibitor that elicited p27 and p21 accumulation in breast cancer cells, which could be 
overcome by the overexpression of CKS1 and Skp2 [162]. Further, the anti-depressant 
drug fluoxetine has recently gained attention due to its anti-proliferative and 
chemosensitizing effects on cancer cells and was the only compound tested in cervical 
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cancer cells so far [163]. Treatment of SiHa as well as MDA-MB-231 breast cancer cells 
with fluoxetine led to a cell cycle arrest in G1 phase by CKS1 downregulation which was 
accompanied by p27 and p21 upregulation [163]. The highest therapeutical and 
therefore possibly also clinical potential is currently attributed to ‘Compound 1’ (C1), a 
specific small molecule inhibitor of the CKS1-p27 interaction [164, 165]. Attenuated 
proliferation after treatment with C1 due to accumulation of p27 and p21 has been 
shown in prostate cancer cells and organoids, as well as for leukemia cell lines [166, 
167]. The effects of C1 have not yet been studied in cervical cancer cells which – in light 
of the results obtained in the present studies – should be an interesting future task. So 
far however, neither C1 nor another CKS1-specific therapy is close to being translated to 
the clinic and tested in humans.  
 
3.2.2 FOXM1 is dispensable for proliferation in HPV-positive cells 
After downregulation of FOXM1 in HPV-positive cells, neither alterations in cell cycle 
distribution nor the induction of senescence or cell death by apoptosis were observed. 
In other words, growth of cervical cancer cells was unaltered by FOXM1 knockdown, 
making FOXM1 dispensable for proliferation in HPV-positive cells. 
This result stands in contrast to the common notion that FOXM1 is required for 
maintaining cellular proliferation and that a FOXM1 knockdown inevitably results in a 
cessation or at least strong impairment of growth. Knockdown or overexpression 
studies of FOXM1 have been reported in various experimental settings and cellular 
backgrounds. For instance, it has been demonstrated that FOXM1 overexpression in 
nasopharyngeal carcinoma cells accelerated proliferation by promoting S phase entry, 
while FOXM1 knockdown in a different cell line from the same cancer entity resulted in a 
cell cycle arrest in the G1 phase [129]. Accordingly, also increased proliferation of 
hepatocellular carcinoma cells after FOXM1 overexpression has been reported [168], 
while diminished cell growth was observed in MCF-7 breast cancer cells after FOXM1 
knockdown [169]. In addition to these direct approaches, inhibition of proliferation by 
treatment with various compounds is attributed to FOXM1 downregulation [170, 171] 
as well as the anti-proliferative effects of several miRNAs [172–174]. Besides, the pro-
proliferative role of FOXM1 is supported by tumor xenograft experiments with ovarian 
cancer cells in mice [175] and in transgenic mouse models for prostate cancer [176]. 
Finally, and in contrast to the results obtained in this work, FOXM1 has been reported to 
act pro-proliferatively also in HPV-positive cell lines, specifically HeLa and SiHa. Notably 
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however, these latter experiments were carried out in stable FOXM1 knockdown cells 
that were cultivated under selection with G418 [95, 128]. As further discussed below, 
my findings that cultivation with G418 or HYG (another antibiotic used for selection 
purposes in CFAs) can impair proliferation of HPV-positive FOXM1 knockdown cells may 
provide an explanation for these discrepant results. 
 
Therefore, in contrast to cells from many other cancer entities, HPV-positive cells seem 
to have overcome their dependency on sustained FOXM1 expression for continuing 
proliferation. This may also in part be explained by E6’s and E7’s ability to prevent 
DREAM formation, therefore circumventing cell cycle arrest in the G1 phase and driving 
continuous cell cycle progression [145]. In line with this proposition, abrogation of the 
G1/S cell cycle checkpoint by E7 expression has been shown [177].  
Additionally however, FOXM1 itself also plays an essential role for undisturbed cell cycle 
progression: During the cell cycle, formation of the transcriptionally activating MMB-
FOXM1 (B-Myb-MuvB-FOXM1) complex occurs after the repressive DREAM complex has 
dissociated through p130 phosphorylation in the late G1 phase. The MuvB core complex 
(previously incorporated in DREAM) then binds to the transcription factor B-Myb during 
S phase, thereby turning from the repressive into a transcriptionally activating complex. 
Subsequently, FOXM1 is recruited to form the B-Myb-MuvB-FOXM1 (MMB-FOXM1) 
complex which is required for activation of gene expression in the G2 and M phases (see 
also fig. 18) [64, 178]. 
So far, it remains an unresolved question, whether B-Myb-MuvB (MMB) are capable of 
activating target genes without the presence of FOXM1 in their complex [179]. This is 
however a possible scenario to explain unaltered proliferation in the absence of FOXM1 
in HPV-positive cells. Given the high redundancy that is characteristic for cell cycle 
regulatory control pathways, there might also be other cellular factors that substitute 
for MMB-FOXM1 activity after FOXM1 knockdown. This speculation is supported by 
results from Rashid et al that report that the MMB complex is not critical for the 
expression of S/G2 genes in HPV16-positive CaSki cells [180]. 
Furthermore, the observations discussed here were obtained in cells were FOXM1 had 
been knocked down using siRNAs. Therefore, although low, residual protein levels of 
FOXM1 could potentially suffice for MMB-FOXM1 formation and unaltered cell cycle 
progression under these experimental conditions. 
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Taken together, the proliferation of HPV-positive cervical cancer cells was shown to be 
unaffected despite efficient knockdown of FOXM1, which has not been observed for cells 
from other tumor types. 
 
3.2.3 The role of FOXM1 in DNA damage repair 
Since FOXM1 repression did not impair proliferation in HPV-positive cells, it was 
unexpected to see a clear reduction of colony outgrowth in CFAs after FOXM1 
knockdown. In addition, the HeLa “p53 null” cell line showed decreased proliferation of 
FOXM1-depleted cells when their stock culture was kept under selection with the 
antibiotic G418. Both compounds, HYG used for selection in CFA and G418, have been 
reported to possess DNA damaging potential in addition to their ability to inhibit protein 
synthesis which mainly accounts for their antibiotic properties [132, 133, 137]. 
Subsequent proliferation studies employing sub-lethal doses of various DNA damaging 
agents confirmed that FOXM1 knockdown selectively sensitized cells to DNA damage, 
resulting in impaired growth. The accumulation of DNA damage was verified by an 
increase in γ-H2AX foci staining. 
 
DNA damage is a daily phenomenon in cells and is for example induced by cellular 
metabolites such as reactive oxygen species, environmental radiation, errors during 
DNA replication or the treatment with genotoxic agents [181]. The latter is a key 
strategy in cancer therapy, with the rationality to preferably kill the faster proliferating 
tumor cells, while the quiescent or slower proliferating cells of the healthy tissues are 
less affected.  To maintain the integrity of their genomes, cells have developed a tightly 
regulated network of DDR pathways that encompasses different repair mechanisms for 
every type of DNA damage.  
The majority of DNA lesions in the cell are base modifications or single-strand breaks 
[182]. They are preferentially repaired by the pathways of base excision repair (BER), 
where only one base is replaced, or nucleotide excision repair (NER), removing and 
replacing a small stretch of damaged DNA [182]. On the other hand, double-strand 
breaks (DSBs) constitute the most toxic type of DNA damage which is also the most 
difficult to repair [183]. Here, cells use two main pathways for repair: homologous 
recombination (HR) and non-homologous end joining (NHEJ) [184, 185]. HR has the 
highest sequence fidelity of the DSB repair mechanisms as it relies on the sequence of 
the sister chromatid as a replication template. It is therefore however restricted to the S 
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and G2 phase of the cell cycle, when two copies of every chromosome are available in 
the nucleus [186]. NHEJ can occur throughout the cell cycle since it is independent of the 
presence of the sister chromatid, but is more error-prone than HR [187]. 
The findings in the present studies indicating that FOXM1 can support resistance of 
HPV-positive cancer cells towards genotoxic stress are supported by previous studies 
which linked FOXM1 to an improved cellular DDR: Increased radioresistance in 
glioblastoma, as well as enhanced resistance to DOX or CDDP treatment in breast and 
ovarian cancer cells, respectively, have been linked to FOXM1 expression [188, 189, 
190]. Moreover, chemoresistant cells and tumors have been found to often contain 
elevated levels of FOXM1 in comparison to their non-resistant counterparts [59, 84, 189, 
191]. Furthermore, FOXM1 knockdown sensitized a panel of different cancer cell lines 
with mutant p53 to DNA damage and increased the rate of apoptosis in these cells [81]. 
On the transcriptional level, XRCC1 (X-ray repair cross complementing 1), a scaffolding 
protein which is mainly required in BER [192], and BRCA2 (breast cancer susceptibility 
gene 2), a key mediator of HR [193], are activated by FOXM1 expression [194] and can 
contribute to FOXM1-mediated CDDP resistance in breast cancer cells [84]. Additional 
molecular targets of FOXM1 in the DDR have been described: Upregulation of 
exonuclease 1 (EXO1) by FOXM1 mediates CDDP resistance in ovarian cancer cells and 
epirubicin resistance in breast cancer cells is conferred by the FOXM1 target BRIP1 
(BRCA1-interacting protein C-terminal helicase 1), which is required for HR [83, 189]. 
Also the HR factor NBS1 (Nijmegen breakage syndrome 1) was found to be 
transcriptionally upregulated by FOXM1 in the DDR [195]. Notably, by analyzing specific 
reporter constructs, FOXM1 knockdown in HeLa cells was found to repress the DDR by 
HR but not NHEJ [59, 195]. In addition, FOXM1 has also been implicated in facilitating 
access of DDR enzymes to DNA damage sites via chromatin remodeling [82]. 
Summing up, FOXM1 enhances the cellular DDR via different pathways and multiple 
targets, its actions thereby possibly depending on cell type and the different kinds of 
DNA lesions encountered. Consistently, in the investigations presented here, the 
protection of cervical cancer cells by FOXM1 towards the chemotherapeutic agents CPT, 
DOX and CDDP was observed independently of the different modes of action of the 
compounds. 
Notably, most of the published studies concerning the interrelation between FOXM1 and 
the DDR were conducted in breast cancer cells, specifically the MCF-7 cell line. However, 
cell type-specific effects may also play a role in this context. Thus far, little is known 
Discussion 
58 
about the mechanisms by which FOXM1 can improve the DDR in HPV-positive cells, an 
issue which awaits further experimental exploitation. In this light, an interesting 
question that remains to be answered is why SiHa cells, in contrast to the other HPV-
positive cell lines investigated, showed no increase in sensitivity towards the combined 
application of FOXM1 knockdown and DNA damage. 
 
Collectively, the findings of the present investigations indicate that the elevated levels of 
FOXM1 due to activation by E6/E7 could be a mechanism to enhance the DDR in HPV-
positive cells which could result in increased chemotherapy resistance. Thus, in 
principle, the sensitivity of HPV-positive cancer cells to chemo- and possibly also 
radiotherapy may be increased by the targeted inhibition of FOXM1. The use of FOXM1 
inhibitors for cancer treatment has long been discussed in the light of FOXM1’s 
tumorigenic properties [196]. However, transcription factors such as FOXM1 are usually 
considered notoriously difficult to target chemically since they often lack druggable 
regions on their surface [197]. Nevertheless, the thiazole antibiotics thiostrepton and 
siomycin A have been identified as FOXM1 inhibitors that lead to downregulation of 
FOXM1 mRNA and protein levels, inhibition of FOXM1 downstream targets and the 
induction of apoptosis [198, 199, 200]. However, while they are often referred to and 
employed as “FOXM1-specific” inhibitors, thiostrepton and siomycin A have actually 
been identified to be proteasome inhibitors [201–203]. In addition, also other well-
characterized proteasome inhibitors such as MG132 and bortezomib can downregulate 
FOXM1 transcript and protein levels [204]. FOXM1 suppression by proteasome 
inhibitors therefore appears to be a general feature, and was shown to be linked to the 
stabilization of HSP70 (heat shock protein 70 kDa) upon proteasome inhibition [205]. Of 
course, proteasome inhibition interferes with multiple cellular pathways and targets, 
therefore raising serious issues with regard to the specificity of action on FOXM1 
inhibition [206, 207]. 
In a high-throughput screening approach, Gormally et al have identified the candidate 
compound FDI-6 which they found to bind specifically to FOXM1 and to suppress 
FOXM1’s binding to target gene promoters [208, 209]. Data regarding the efficacy of 
FDI-6 in cell culture or in vivo studies are however still missing. Recently, a potential 
drug-binding pocket within the FOXM1 DNA binding domain was identified and 
reported to mediate the direct binding of FDI-6 and thiostrepton [200, 210].  
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Despite extensive research efforts, a bona fide FOXM1 inhibitor with significant clinical 
potential is therefore still lacking. Nevertheless, FOXM1 suppression remains an 
attractive therapeutic strategy and could have chemosensitizing effects, not only for 
HPV-positive tumors. Indeed, combination experiments have identified a synergistic 
relationship between the clinically approved proteasome inhibitor bortezomib and 
CDDP treatment in lung and cervical cancer cells [211, 212]. Whether this effect is 
accompanied and/or mediated by FOXM1 suppression was however not investigated. 
 
3.2.4 FOXM1 and CKS1 in proliferative arrest 
Both FOXM1 and CKS1 have been reported to play essential roles in regulating cell cycle 
progression in proliferating cells and the viral oncogenes E6 and E7 activate 
proliferation in their host cells. It was therefore also important to investigate whether 
the elevated levels of FOXM1 and CKS1 were simply a secondary effect of the higher 
proliferation rate of HPV-positive cells while vice versa the downregulation of both 
genes upon E6/E7 silencing resulted from the proliferative halt of the cells induced by 
viral oncogene repression. 
Treatment with the DNA replication inhibitor HU effectively arrested HeLa and SiHa 
cells in the G1 or S phase, respectively, while leaving the viral oncogene expression 
unaltered. Interestingly, under these conditions, neither FOXM1 nor CKS1 protein levels 
declined. Also by the use of other cell cycle inhibitors that arrest cells at different stages 
of the cell cycle, no decrease of FOXM1 or CKS1 levels was witnessed in HPV-positive 
cells as long as E7 was expressed. 
These observations preclude FOXM1 and CKS1 from being mere proliferation markers in 
HPV-positive cancer cells as their sustained expression is not dependent on active 
proliferation. They also challenge the current general concept that FOXM1 expression is 
strictly limited to proliferating cells [48–50] and declines after the induction of 
senescence [51]. Notably, HU treatment was demonstrated to induce senescence under 
the conditions employed here [213]. By incorporating the mechanisms of FOXM1 and 
CKS1B promoter activation by E6/E7 described in this dissertation, a new model taking 
into account the specific background of HPV-positive cells could be proposed: While the 
cells do undergo proliferative arrest after treatment with the respective cell cycle 
inhibitors, the repressive DREAM complex is not formed due to the continuing 
expression of the HPV oncogenes, thereby keeping expression from the FOXM1 and 
CKS1B promoters active. Sustained expression of E6 also disables p53 checkpoint 
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activity. In addition, continuing E2F1 signaling stimulates the FOXM1 promoter since E7 
prevents pRb from sequestering E2F1. This model could also explain why the cell cycle 
phase in which the cells arrest does not affect ongoing FOXM1 and CKS1 expression: The 
cell cycle-dependent expression pattern of FOXM1 and CKS1 is presumably deregulated 
and overridden due to the abolition of DREAM. It would be interesting to further 
corroborate these ideas with additional experiments, for example using synchronized 
proliferating cells or by performing knockdown studies of E2F1 or DREAM components. 
While the overall regulation of FOXM1 and CKS1 levels seems to be consistent in 
HeLa and SiHa cells, some differences were observed: Cell cycle arrest by dNTP 
depletion following HU treatment occurred in the G1 phase for HeLa cells, while SiHa 
cells arrested during S phase. This possibly may reflect an impaired replication stress 
checkpoint at the G1/S border in SiHa cells. Additionally, mimosine treatment, which 
also induces replication stress due to inhibition of the ribonucleotide reductase [214], 
led to a downregulation of E7 in SiHa, but not in HeLa cells. This downregulation of E7 
was accompanied by a decrease of CKS1 protein, supporting the activating role of E7 on 
CKS1 levels. Perhaps surprisingly however, FOXM1 levels stayed elevated despite the 
absence of E7, pointing to an additional cellular mechanism which supports FOXM1 
expression under these conditions. Notably, treatment with HU, mimosine and 
thymidine is also known to induce DNA damage and activate the DDR [215–217]. Hence, 
FOXM1 upregulation in treated cells could possibly result from an activated DDR. 
 
The next question to answer was whether the unexpected phenomenon of FOXM1 
upregulation after cell cycle arrest is specific to HPV-positive cells. HU treatment of HPV-
positive and -negative tumor cell lines as well as HPV-negative primary fibroblasts was 
carried out over a longer time period (72 h) and with increasing doses of HU. While 
FOXM1 levels stayed elevated in the HPV-positive cell lines also at higher doses of HU 
and later time points, downregulation of FOXM1 after prolonged cell cycle arrest was 
observed in primary fibroblasts and HPV-negative MCF-7 and H1299 cells. As 
functionality of the pocket protein family is not known to be impaired in these cells, 
sustained proliferative arrest should result in the activation of pRb, p107 and p130 and 
the subsequent formation of DREAM and induction of senescence [218], accompanied by 
a downregulation of FOXM1. 
Sustained FOXM1 levels after growth arrest are however not only restricted to HPV-
positive cells: The bladder cancer cell line 5637 also showed continuing FOXM1 
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expression after HU treatment. In contrast to the other cell lines investigated here, 5637 
cells carry a genomic deletion of the RB1 gene. While this should, in theory, not affect 
DREAM formation, E2F1 sequestration by pRb is unattainable in these cells. 
Speculatively, this situation could therefore mimic the inactivation of pRb by E7, and 
therefore promote FOXM1 expression via E2F1 transactivation. This hypothesis could be 
further investigated by extending these experiments to additional cell lines with 
different mutational backgrounds (p53 mutation, additional pRb-mutated or -deleted 
cell lines). 
In summary, despite being usually confined to actively proliferating cells, FOXM1 
expression is sustained in growth-arrested HPV-positive cells. This effect could be 
mediated by continuing expression of the viral oncogenes, which cause DREAM 
disruption and ongoing E2F1 signaling.  
 
 
3.3 Summary and conclusions 
In the present studies, FOXM1 and CKS1B could be identified as novel target genes of the 
HPV oncogenes E6 and E7. Both mRNA and protein levels of FOXM1 and CKS1 are 
elevated by E6/E7, and this upregulation was shown to take place, at least in part, via 
stimulation of the transcriptional promoters of FOXM1 and CKS1B. Each of the viral 
oncoproteins was able to independently activate the target gene promoters and this 
stimulatory effect was further increased upon combined E6 and E7 expression. 
FOXM1 and CSK1B have been identified previously as target genes of the repressive 
DREAM complex which silences expression of cell cycle genes during quiescence and 
early G1 phase [157]. E6 and E7 both can interfere with DREAM formation and therefore 
abrogate repression of its target genes: E7 sequesters the pocket proteins p130 or p107 
which make up an essential part of the DREAM multi-protein complex while the 
degradation of p53, which is initiated by E6, inactivates the p53-p21 axis that usually 
controls DREAM retention after p53 checkpoint activation [148]. Moreover, the 
formation of the transcriptionally activating MMB-FOXM1 complex that regulates 
expression of S/G2 cell cycle genes is promoted by HPV E7 [219]. It therefore seems a 
valid conclusion that the activating effect of HPV E6/E7 on the FOXM1 and CKS1B 
promoters is at least partially mediated by disruption of the DREAM complex. In 
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addition, FOXM1 expression was also found to be activated by E2F1 via disturbance of 
the pRb-E2F1 interaction through E7. 
While CKS1B expression is described to be transcriptionally controlled by FOXM1 
through the MMB-FOXM1 complex [41, 143], the activating effect of E6/E7 on the CKS1B 
promoter was shown to occur independent of FOXM1 expression, precluding CKS1B 
activation from being a downstream effect of FOXM1 upregulation in HPV-positive cells 
and establishing it as an independent target gene of E6/E7. In addition, a p53-
independent component of CKS1B promoter stimulation by E6 was observed in H1299 
cells. 
On the phenotypic level, CKS1 upregulation was shown to have a pro-proliferative and 
senescence-suppressing effect in cervical cancer cells. FOXM1 expression, on the other 
hand, was dispensable for the proliferation of HPV-positive cells, which stands in 
interesting contrast to cell lines from other cancer entities [129, 168, 169]. Apparently, 
HPV-positive cancer cells have found a way to overcome the dependency on FOXM1 
expression for proliferation that is observed in other cancer types [75, 76]. Importantly 
however, FOXM1-depleted HPV-positive cancer cells were sensitized towards genotoxic 
agents, indicative of a role for FOXM1 in enhancing their chemoresistance. Neither 
FOXM1 nor CKS1 were found to decline during cell cycle arrest when HPV oncogene 
expression is maintained, in line with the concept that they are stimulated as a result of 
E6/E7-induced DREAM complex disruption.  
 
Collectively, the findings of this dissertation identified FOXM1 and CKS1B as functionally 
relevant novel target genes for oncogenic HPVs and have shed new light onto the 
virus/host cell crosstalk in HPV-positive cancer cells. They provide insights into the 
molecular mechanisms of FOXM1 and CKS1B stimulation by the HPV E6/E7 oncogenes 
and delineate the resulting phenotypic consequences for HPV-positive cancer cells. 
Moreover, the observations that the proliferation of HPV-positive cancer cells was 
efficiently blocked after CKS1B knockdown, and that the suppression of FOXM1 had a 
chemosensitizing effect, indicate that FOXM1 and CKS1 inhibition could be a promising 
novel strategy for the treatment of HPV-linked (pre-)neoplasias. 
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4 Material and Methods 
 
4.1 Reagents 
All reagents used were molecular biology grade where possible. All standard reagents 
for buffers and media were supplied by AppliChem (Germany), Applied Biosystems 
(USA), BD Biosciences (Germany), BioRad (USA), Carl Roth GmbH (Germany), Enzo Life 
Science (Germany), Fisher Scientific (USA), GE Healthcare (United Kingdom), Gerbu 
(Germany), Gibco (USA), Invitrogen (USA), Merck (Germany), Promega (USA), Roche 
Diagnostics (Switzerland), Saliter (Germany), and Sigma-Aldrich (Germany). 
Manufacturers of specific reagents are named in the text. 
Buffers and solutions were prepared using dH2O. 
 
 
4.2 Cell-based methods 
4.2.1 Cell culture 
All cells were cultured in Dulbecco’s minimal essential medium (DMEM, Gibco, Thermo 
Fisher Scientific, USA), except for 5637 bladder carcinoma cells which were maintained 
in RPMI-1640 medium (Gibco). The standard medium was supplemented with 10% fetal 
calf serum (FCS, Gibco), 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine 
(“PSG”, all from Sigma-Aldrich) for all cell lines. Standard cultivation was performed at 
37 °C and 5% CO2 in a humidified atmosphere. 
For routine passage, cells were split twice a week using 0.25% trypsin-EDTA solution 
(Gibco) for detachment. Cell cultures were supplied with fresh medium at least every 
3 days. 
For live cell proliferation analyses HeLa, SiHa and CaSki cells were transduced with a 
pMOWS hH2B mCherry expression vector, generating cells with a red fluorescent 
nucleus. Transduction of HeLa and SiHa cells was kindly performed by Dr. Joschka 
Willemsen, group of Dr. Marco Binder, DKFZ, Heidelberg. The newly generated cell lines 
were termed HeLa, SiHa or CaSki mCherry H2B, respectively, and were kept in stock 
medium containing puromycin (Alexis Biochemicals) for selection. The HeLa “p53 null” 
cell line contains a stably integrated shRNA against TP53 and was generated by 
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Hengstermann et al [121]. For selection purposes its stock culture is maintained in 
DMEM supplemented with 700 µg/mL G418 (Gibco). For experiments, all selection 
agents were omitted from the media. An overview of all cell lines utilized in this thesis is 
provided in table 1. 
For experiments, cells were either seeded in 6 cm dishes filled with 3 mL medium, or in 
96 well plates with 100-200 µL medium. Typical cell seeding densities for 96 well plates 
are listed in table 2. Cells were counted using the CountessTM Automated Cell Counter 
(Invitrogen, Carlsbad, USA) after staining with trypan blue. 
 
Table 1: Human cell lines and media 
Cell line Origin Medium 
5637 urinary bladder carcinoma RPMI-1640 
CaSki 
HPV16-positive cervical cancer, epidermoid 
carcinoma 
DMEM 
CaSki mCherry H2B 
HPV16-positive cervical cancer, epidermoid 
carcinoma 
DMEM + 0.5 µg/mL 
puromycin 
CxF6 uterine cervix primary fibroblasts DMEM 
Fib101 adult primary fibroblasts from abdominal skin DMEM 
H1299 non-small cell lung cancer DMEM 
HeLa HPV18-positive cervical adenocarcinoma DMEM 
HeLa “p53 null” HPV18-positive cervical adenocarcinoma 
DMEM + 700 µg/mL 
G418 
HeLa mCherry H2B HPV18-positive cervical adenocarcinoma 
DMEM + 1 µg/mL 
puromycin 
MCF-7 breast adenocarcinoma DMEM 
SiHa HPV16-positive cervical squamous cell carcinoma DMEM 
SiHa mCherry H2B HPV16-positive cervical squamous cell carcinoma 
DMEM + 1 µg/mL 
puromycin 
 
Table 2: Seeding densities in 96 well plates 
Cell line Cells/well 
CaSki mCherry H2B 4500 
HeLa “p53 null” 2000 
HeLa mCherry H2B 1500 
SiHa mCherry H2B 3000 
 
4.2.2 Cryopreservation and thawing of cells 
For long-term storage, cells were trypsinized, pelleted by centrifugation at 800 x g, 
resuspended in culture medium containing 30% FCS and 10% DMSO and aliquoted into 
cryotubes. The cryotubes were transferred into an isopropanol-filled freezing container 
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(Nalgene, Thermo Fisher Scientific) and kept at -80 °C for several days before final 
storage in liquid nitrogen. 
For thawing, cells were rapidly warmed to 37 °C in a water bath, resuspended in fresh 
culture medium and transferred into a new cell culture flask. Medium was exchanged 
the next day. 
 
4.2.3 NOK cells 
HPV-negative normal oral keratinocytes (NOKs), immortalized by the introduction of 
hTERT, were stably transduced with HPV16E6/E7 using lentiviral gene transfer. Cell 
line generation and culture were performed by Ruwen Yang, group of Prof. Frank Rösl, 
DKFZ, Heidelberg. Protein extracts were also generously provided by Ruwen Yang. 
Detailed experimental procedures are described in [220]. 
  
4.2.4 Treatment of cells with chemical compounds 
If not indicated otherwise, cells were treated one day after seeding, or 24 h post 
transfection. Fresh medium was supplied before treatment. The same concentration of 
solvent was added to control cells. For long-term treatment experiments with 
hydroxyurea (HU), medium was exchanged and supplemented with freshly prepared HU 
every 24 h. 
All chemical compounds employed, including manufacturer, stock concentration and 
solvent used, are given in table 3. If not noted otherwise, stock solutions were stored 
at -20 °C. 
 
Table 3: Chemical compounds 
Compound 
Stock 
concentration 
Solvent Manufacturer 
 
Camptothecin 
(CPT) 
5 µM DMSO Cayman Chemical 
pre-dilution 1:1000 in 
DMEM 
Cisplatin (CDDP) 3.3 mM 0.9% NaCl Merck stored at RT 
Doxorubicin 
(DOX) 
50 µM H2O Enzo Life Sciences 
 
Hydroxyurea 
(HU) 
500 mM H2O Calbiochem 
prepared freshly 
Hygromycin B 
(HYG) 
50 µg/mL - Invitrogen 
stored at 4 °C 
Mimosine 50 mM 10% NaHCO2 Santa Cruz  
Nocodazole 10 mg/mL DMSO Calbiochem  
Thymidine 200 mM PBS Thermo Scientific  
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4.2.5 Transfection of siRNAs using Dharmafect 
RNA interference (RNAi) efficiently silences expression of a selected gene using small 
interfering RNAs (siRNAs) spanning a unique sequence within the target gene’s mRNA. 
Synthetic siRNAs are usually 19 bp long and double-stranded, with a 2-nucleotide 
overhang at the 3’-ends. Upon transfection into the cell, they are incorporated into the 
cellular RISC (RNA-induced silencing complex), where they mediate mRNA degradation 
of their target gene. 
For transfection, cells were seeded in 6 cm dishes at medium density to reach 40-50% 
confluency the next day. Then, the cell-line specific amount of Dharmafect I 
(Dharmacon) (see table 4) was mixed with the respective amount of OPTI-MEM (Gibco) 
to reach 200 µL and was incubated at room temperature (RT) for 5 min. Meanwhile, 
198 µL OPTI-MEM were prepared with 2 µL siRNA stock (10 µM in nuclease-free H2O, 
Ambion Silencer Select, Thermo Fisher Scientific) to yield a final siRNA concentration of 
10 nM during transfection. Both mixtures were combined and incubated for another 
20 min at RT. Meanwhile, medium in the 6 cm dishes was exchanged to 1.6 mL of 
PSG-free DMEM, supplemented with 10% FCS. The transfection mix (final volume 
400 µL) was added dropwise to the cells. Medium was exchanged to 3 mL of full medium 
after 24 h.  
For transfection in 96 well plates, volumes were adjusted as following: 20 µL of final 
transfection mix were prepared per well and added to 80 µL of PSG-free DMEM. Medium 
was exchanged to 200 µL of full medium after 24 h. 
For transfection of control cells, siContr-1 was used, which contains at least 4 
mismatches to all known human genes. All sequences of siRNAs utilized are listed in 
table 5. Where possible, a pool of 2-3 siRNAs was used at equimolar concentrations to 
minimize off-target effects. 
 
Table 4: Dharmafect I concentrations depending on cell line 
Cell line Final concentration of Dharmafect I in transfection  
HeLa 0.2% 
HeLa mCherry H2B 0.2% 
HeLa “p53 null” 0.2% 
SiHa 0.3% 
SiHa mCherry H2B 0.4% 
CaSki mCherry H2B 0.3% 
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Table 5: siRNA sequences 
siRNA Sequence (5’ -> 3’) Pool 
siContr-1 CAGUCGCGUUUGCGACUGG  
si16E6-4 ACCGUUGUGUGAUUUGUUA 
si16E6 si16E6-246 GGGAUUUAUGCAUAGUAUA 
si16E6-321 UUAGUGAGUAUAGACAUUA 
si16E6/E7-2 CCGGACAGAGCCCAUUACA 
si16E6/E7 si16E6/E7-575 CACCUACAUUGCAUGAAUA 
si16E6/E7-617 CAACUGAUCUCUACUGUUA 
si18E6-340 GACAUUAUUCAGACUCTGU 
si18E6 si18E6-349 CAGACUCUGUGUAUGGAGA 
si18E6-353 CUCUGUGUAUGGAGACACA 
si18E6/E7 CCACAACGUCACACAAUGU 
si18E6/E7 si18E6/E7-563 CAGAGAAACACAAGUAUAA 
si18E6/E7-846 UCCAGCAGCUGUUUCUGAA 
siCKS1-1 GGACAUAGCCAAGCUGGUC 
siCKS1 
siCKS1-3 UGGUGACUUGCGGAUUUAU 
siFOXM1-2 AACAUCAGAGGAGGAACCU 
siFOXM1 
siFOXM1-3 UGGGAUCAAGAUUAUUAAC 
 
 
4.2.6 Transfection of plasmid DNA 
Phosphate-buffered saline (PBS) 
137 mM NaCl 
2.7 mM KCl 
4.3 mM Na2HPO4 
1.4 mM KH2PO4 
pH 7.4 
autoclaved before use 
 
BES buffer 
50 mM BES 
280 mM NaCl 
1.5 mM Na2HPO4 
pH 6.95 
filter-sterilized before use 
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For transfection of plasmid DNA, the calcium phosphate coprecipitation method by Chen 
and Okoyama was used [221]. In brief, cells were seeded in 6 cm dishes at low density in 
3 mL full DMEM, to reach ca. 30% confluency the next day. Plasmid DNA was mixed with 
150 µL 0.25 M CaCl2, then 150 µL of BES buffer was added. The mixture was incubated 
for 15 min at RT and then added dropwise to the cell culture dish. The cells were kept in 
a humidified incubator at 35 °C and 3% CO2 for 16-18 h, before removing the medium, 
washing 2 times with PBS and adding 3 mL of fresh medium. HeLa cells were only 
washed once with PBS. The cells were then incubated at standard conditions and 
harvested 48 h after transfection for overexpression experiments and 72 h after 
transfection if knockdowns were performed.  
Per 6 cm dish, 6-7.3 µg of total DNA were transfected. Where necessary, lower DNA 
amounts were filled up with pBlueScript II vector (pBS) to reach 6 µg. The pSUPER 
vector carries an expression cassette for small hairpin RNAs (shRNAs). They mediate 
gene silencing comparable to siRNAs (see 4.2.5) after processing by the cellular Dicer 
complex. The episomal pCEPsh vector additionally also allows for selection of 
transfected cells by conveying resistance to hygromycin B, thereby enabling long-term 
expression of the shRNAs. A list of all plasmids used in this project is provided in the 
appendix (table 12). 
 
4.2.7 Luciferase reporter gene assay 
Trisphosphate lysis buffer 
25 mM glycylglycine, pH 7.8 
15 mM MgSO4 
4 mM EGTA 
1 mM DTT 
10% glycerol 
1% Triton X-100 
 
Luciferase reaction buffer 
25 mM glycylglycine, pH 7.8 
15 mM MgSO4 
5 mM ATP 
prepared freshly before use from 10x buffer and 50 mM ATP-solution 
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Luciferin solution 
0.25 M luciferin in ATP-free luciferase reaction buffer 
 
The luciferase reporter gene assay allows to study the promoter activity of a gene of 
interest, by cloning said promoter or fragments thereof in front of the firefly luciferase 
gene. The amount of expressed luciferase enzyme in transfected cells then directly 
correlates with the activity of the investigated promoter under the respective 
experimental conditions. It is quantified by measuring the amount of light emitted 
during oxidation of its substrate luciferin, using a luminometer. To normalize for 
variations in transfection efficiency between samples, a β-galactosidase assay (see 4.2.8) 
on co-transfected β-galactosidase reporter plasmid pCMV-Gal was performed in parallel. 
As p53 and E2F1 overexpression were observed to repress β-galactosidase expression 
from the pCMV promoter, Bradford assay (see 4.3.1) was performed in these 
experimental settings to normalize on total protein amount. 
The respective plasmid mix was delivered to the cells using the calcium phosphate 
coprecipitation method (see 4.2.6). 0.2 µg pCMV-Gal were co-transfected in all samples. 
48 h after transfection (for overexpression experiments) or 72 h after transfection (for 
knockdown experiments) cells were harvested: The medium was discarded, cells were 
washed once with cold PBS, and scraped in 200 µL trisphosphate lysis buffer. The lysed 
sample was transferred to a 1.5 mL-tube and undissolved cell debris was pelleted during 
centrifugation for 5 min at 16100 x g, 4 °C. 30 µL of the supernatant were transferred to 
a solid white 96 well plate for the luciferase activity measurement and the same amount 
was also pipetted into a transparent 96 well plate for the β-galactosidase assay. 
Trisphosphate lysis buffer was used as blank for both assays. Using a LB943 Mithras2 
luminometer (Berthold Technologies, Bad Wildbad, Germany), luciferase activity was 
detected by measuring emission at 562 nm over 10 sec directly after injection of 150 µL 
luciferase reaction buffer and 50 µL luciferin solution into the sample. All experimental 
conditions were assessed in biological duplicates. 
For evaluation, the luminometer blank value was subtracted from the readings, and the 
results were normalized for transfection efficiency using the respective β-galactosidase 
assay value. The mean of the duplicates was generated.  
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4.2.8 β-Galactosidase assay 
β-Galactosidase reaction buffer 
60 mM Na2HPO4 
40 mM NaH2PO4 
10 mM KCl 
1 mM MgSO4 
1 mg/ml ortho-Nitrophenyl-β-galactoside 
 
200 µL of reaction buffer were added to 30 µL cell lysate in a transparent 96 well plate. 
After a suitable time (ca. 5-30 min depending on the transfection efficiency) a yellow 
colouring can be observed. The absorbance was then measured at 405 nm using the 
Multiskan Ex ELISA plate reader (Thermo Electron, Karlsruhe, Germany). Absorbance at 
620 nm was subtracted to minimize plate background. 
 
4.2.9 TUNEL assay for apoptosis detection 
The terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay labels 
the exposed 3’-hydroxyl termini of nuclear DNA that are generated during apoptosis. 
Chromatin fragmentation is a relatively late event in apoptosis and occurs when cellular 
endonucleases cleave the DNA at their only accessible site, between the nucleosomes. It 
can be detected over a wide range of cell types and apoptotic stimuli [222]. 
Cells were seeded on glass coverslips in 6 cm dishes. At the given time point, coverslips 
were removed from the dish, washed once in PBS and fixed in 4% formaldehyde 
solution for 30 min at RT. They were then washed twice with PBS and permeabilized in 
cold 0.1% Triton-X100, 0.1% sodium citrate in PBS for 2 min. (If necessary, coverslips 
may be stored in 70% EtOH at -20 °C for up to several weeks before permeabilization.) 
Before staining, coverslips were again washed twice in PBS and placed in a wet chamber. 
Using the In situ Cell Death Detection kit, fluorescein-coupled (Roche, Germany), cells 
were incubated with 25 µL TUNEL staining solution (solution 1:solution 2 - 1:9) at 37 °C 
for 60-90 min. Afterwards, coverslips were 5x dip-washed in PBS and left in fresh PBS 
for 2x 10 min. They were then incubated with 1 µg/mL DAPI (Roche, Germany) for 5 
min at RT in the dark. After 5x dip-wash and 2x 10 min wash in PBS, coverslips were air-
dried and mounted on microscope glass slides using Vectashield (Vector Laboratories 
Inc., USA). Transparent nail polish was used for sealing. Images were acquired the next 
day using a Zeiss motorized inverted Cell Observer.Z1 with LED module Colibri.2 and 
Material and Methods 
73 
the 20x/0.4 LD PlnN Ph2 DICII objective. The Fiji distribution of ImageJ 1.47q was used 
for image adjustment and representation. 
 
4.2.10 Senescence assay 
Senescence assay fixation buffer 
2% formaldehyde 
0.2% glutaraldehyde 
in PBS 
 
Senescence assay staining buffer 
40 mM citric acid 
150 mM NaCl 
2 mM MgCl2 
adjusted to pH 6.0 with Na2HPO4  
5 mM K3[Fe(CN)6]* 
5 mM K4[Fe(CN)6]* 
1 mg/ml X-Gal in DMF* 
*freshly added 
 
Senescence describes the state of cells that have terminally exited the cell cycle and 
irreversibly ceased to proliferate. In these cells, the enzyme senescence-associated β-
galactosidase (SA-β-Gal) is expressed and shows activity at pH 6.0 [223]. It can be 
detected using the chromogenic substrate X-Gal (5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside) which results in blue staining of senescent cells. 
72 h after transfection, cells were split into 6 cm dishes and cultivated under standard 
conditions for 3 additional days. The respective split ratios for each experiment are 
indicated in the figure legends. Cells were then washed with PBS and fixed with 1 mL 
senescence assay fixation buffer for 3 min. After washing with PBS, cells were incubated 
with 1.5 mL senescence assay staining buffer for 24 h at 37 °C in a wet chamber. After 
washing with PBS, representative images were acquired using the EVOSxl Core Cell 
Imaging System brightfield microscope (Life Technologies, USA) with 20-40x 
magnification. 
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4.2.11 Colony formation assay (CFA) 
CFA buffer 
12 mM crystal violet solution 
29 mM NaCl 
3.7% formaldehyde 
22% EtOH 
 
48 h after transfection with pCEPsh plasmids, cells were split. The next day, 
hygromycin B (HYG) was added to the medium. Cell line-specific HYG concentrations are 
provided in the figure legends. Fresh medium with HYG was supplied every 3-4 days for 
1-2 weeks until colonies had formed and all cells in a mock transfected dish had died. 
Cells were then washed with PBS and stained with 350 µL CFA buffer for 5 min. 
Excessive dye was washed out with water and dishes were dried before scanning the 
images with the Epson Perfection 4990 Photo Scanner. 
 
4.2.12 Cell cycle analysis 
During the cell cycle, cellular DNA content doubles from G0 or G1 phase through DNA 
synthesis in S phase to G2 phase. Cell division (mitosis, M phase) then yields two 
individual cells with a complete set of chromosomes each. Using DNA-intercalating dyes 
like propidium iodide (PI), cells may be analysed by their DNA content in a flow 
cytometer. 
72 h after transfection, cells were washed once with PBS and harvested using 
trypsination. Cells were pelleted and washed once again with PBS. All centrifugation 
steps were carried out at 100 x g, 5 min, 4 °C. Cells were resuspended in 300 µL cold PBS 
and 900 µL ice-cold EtOH were added for fixation. After immediate vortexing, cells were 
left at -20 °C for 1 h to several days. EtOH was removed, cells were resuspended in 25 
µg/mL PI, 500 µg/mL RNAse in 1 mL PBS, and incubated for 30 min at RT in the dark. 
The cell suspension was filtered through gauze and analysed at the BD LSR Fortessa flow 
cytometer (BD, Germany) with the BD FACS Diva software v8.0.1. Analysis and image 
generation was performed with FlowJo v10. The Dean-Jett-Fox model was employed to 
generate and quantify cell cycle profiles. 
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4.2.13 EdU assay 
To verify that cells were indeed growth-arrested after HU treatment, a flow cytometry-
based EdU assay was conducted. EdU (5-Ethynyl-2'-deoxyuridine) is a nucleoside 
analogon to thymidine which is incorporated into newly synthesized DNA of 
proliferating cells. Using the EdU-Click 647 Kit (baseclick, Germany), the EdU is then 
detected via click chemistry coupling to a fluorescent dye. 
Cells were treated with 1 mM HU for 48 h, and 2 h prior to harvest, 10 µM EdU was 
added to the dishes. As background control for the click reagent, one dish per condition 
was left without EdU. Cells were harvested and fixed as described for the cell cycle 
analysis (see 4.2.12). All centrifugation steps were carried out at 100 x g, 5 min, 4 °C. 
After removal of EtOH, cells were washed 2 mL PBS, pelleted and resuspended in 100 µL 
saponin-based permeabilization and wash buffer. 500 µL freshly prepared click assay 
cocktail was added and incubated for 30 min at RT in the dark. After washing with 2 mL 
saponin-based permeabilization and wash buffer, cells were resuspended in 25 µg/mL 
PI, 500 µg/mL RNAse in 1 mL PBS, and incubated for 30 min at RT in the dark. The cell 
suspension was filtered through gauze and analysed at the BD LSR Fortessa flow 
cytometer with the BD FACS Diva software v8.0.1. Analysis and image generation was 
performed with FlowJo v10. 
 
4.2.14 Assessing cellular proliferation using the IncuCyte live cell imaging system 
For proliferation studies, cells were seeded in 96 well plates according to the cell 
numbers given in table 2. After transfection and treatment with DNA damaging agents, 
cells were placed in the IncuCyte S3, and proliferation was monitored for up to 120 h. 
4 images per well (phase plus red fluorescence (acquisition time 400 msec), where 
applicable) were acquired every 6 h at 10x magnification. Each experimental condition 
was analysed in triplicates. Proliferation was either assessed by calculating absolute cell 
numbers (Red Object Count (1/Well)) for H2B mCherry labelled cell lines, or by 
analysing confluence (Phase Object Confluence (percent)) for unlabelled cell lines. Image 
analysis was performed using the IncuCyte S3 2018A software. 
 
4.2.15 Immunofluorescence 
Cells were seeded on glass coverslips and harvested at the given time points. Coverslips 
were removed from the medium, washed once in PBS and fixed in 4% formaldehyde 
solution for 4 min. Cells were then washed with PBS, permeabilized in 0.1% Triton-X100 
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in PBS for 5 min, washed again in PBS and blocked in 5% BSA, 0.3 M Glycine, 0.1% 
Triton-X100 in PBS for 20 min at RT. Coverslips were then transferred to parafilm in a 
wet chamber and incubated with 30 µL of primary antibody (mouse anti-P-Ser139-
H2AX No. 05-636 from Millipore, Germany) diluted 1:100 in 3% BSA, 0.1% Triton-X100 
in PBS for 1 h. After 5x dip-wash in PBS, 30 µL of secondary antibody (donkey anti-
mouse, Cy3-conjugate from Pierce Antibodies) diluted 1:400 in 3% BSA, 0.1% Triton-
X100 in PBS with 1 µg/mL DAPI was applied and incubated for 45 min at RT in the dark. 
Coverslips were 5x dip-washed in PBS, once in H2O, once in 100% EtOH and air-dried, 
before mounting on glass coverslips using Vectashield as mounting medium. Before 
image acquisition, the coverslips were sealed using transparent nail polish. Images were 
acquired with the Zeiss motorized inverted Cell Observer.Z1 with LED module Colibri.2 
and the 40x/0.75 EC PlnN Ph2 objective. 
 
 
4.3 Protein-based methods 
4.3.1 Protein extraction and sample concentration equilibration 
CSK-1 lysis buffer 
10 mM PIPES pH 6.8 
300 mM NaCl 
1mM EDTA 
300 mM sucrose 
1 mM MgCl2 
0.5% Triton X-100 
 
100 μl PhosSTOP phosphatase inhibitor cocktail (Roche Diagnostics, Switzerland), 25 μl 
Pefablock (Merck, Germany) and 10 μl P8340 protease inhibitor cocktail (Sigma-Aldrich, 
USA) were added to 900 μl CSK-1 lysis buffer freshly before use. 
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4x SDS-PAGE loading buffer 
8% SDS 
250 mM Tris-HCl 
20% β-mercaptoethanol 
40% glycerol 
0.008% bromophenol blue 
 
For cell harvest, medium was discarded, cells were washed once with PBS and scraped 
with a plastic cell scraper in 500 µL PBS. The cell suspension was transferred to a 1.5 mL 
tube, pelleted and PBS was removed. The cell pellet was stored at -80 °C for up to a few 
days if necessary or was directly lysed in 20-50 µL CSK-1 lysis buffer according to pellet 
size. After 30 min incubation on ice, the lysate was centrifuged at 16100 x g, 5 min, 4 °C 
and the supernatant was transferred to a fresh tube. 
For determination of protein concentration, Bradford assay was performed. 1-3 µL of 
the cell lysate was added to 1 mL freshly prepared Bio-Rad Protein Assay Dye reagent 
(diluted 1:5 with H2O from reagent concentrate; Bio-Rad, Germany) in a disposable 
cuvette and mixed well. Absorption at 595 nm was measured using a BioPhotometer 
D30 (Eppendorf, Germany). Final protein concentration was determined by adjusting to 
a BSA standard curve. Protein lysates were then equilibrated to the desired 
concentration (usually 3 µg/µL) by addition of appropriate volumes of CSK-1 and 
4x SDS-PAGE loading buffer. Samples were heated to 96 °C for 5 min and stored 
at -20 °C/ -80 °C for long-term storage. 
 
4.3.2 SDS-PAGE 
SDS-PAGE running buffer 
2.5 mM Tris 
19.2 mM glycine 
0.1% SDS 
 
In SDS-PAGE (Polyacrylamide gel electrophoresis), protein samples are run through a 
gel under denaturing conditions to achieve separation by size. 
Gels were cast using the disposable Novex Empty Gel Cassettes Mini (Life Technologies, 
Germany) or same-sized reusable glass plates as casing. Glass plates were sealed with 
1% agarose at the bottom to prevent leaking of the gel. Recipes for separation and 
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stacking gels are given in table 6. After casting, gels were wrapped in papers soaked with 
SDS-PAGE running buffer and stored at 4 °C, for at least one day before running the gel. 
After placing the gels in the Xcell SureLockTM Mini-Cell Electrophoresis System (Life 
Technologies, Germany) filled with SDS-PAGE running buffer, gels were loaded with 
10-21 µg of protein extract per lane. 1-2 µL of peqGOLD Protein-marker IV (PeqLab) was 
used as marker. Gels were run at 110 V for 1.5-2 h. 
 
Table 6: SDS-PAGE: Recipe for 2 separation and stacking gels 
Component 
Separation 
gel (12.5%) 
 
Stacking gel 
(5%) 
H2O 5.7 mL  2 mL 
3 M Tris-HCl (pH 8.9) 1.8 mL 0.47 M Tris-HCl (pH 6.7) 1.2 mL 
30% acrylamide/bisacrylamide 5.5 mL  620  µL 
10% SDS 137.5 µL  45.8 µL 
10% APS 176 µL  183.3 µL 
TEMED 3.4 µL  1.8 µL 
 
 
4.3.3 Western blot and immunodetection 
Western Blot buffer 
2.5 mM Tris 
19.2 mM glycine 
20% MeOH 
pH 8.3 
 
PBS-T 
0.2% Tween-20 
in PBS 
 
Directly after SDS-PAGE, the gel cassette was disassembled and the proteins were 
transferred to Immobilon-P PVDF membrane (Millipore, Bedford, USA) using semi-dry 
blotting. To this end, the membrane was shortly activated in MeOH and then incubated 
in Western Blot buffer. 8 Whatman paper pieces (GE Healthcare, UK) were soaked in 
Western Blot buffer, and 4 of them were placed on the bottom of the Trans-Blot® SD 
Semi-Dry Electrophoretic Transfer Cell (Bio-Rad, Germany). This was followed by the 
activated membrane, the gel and another 4 pieces of Whatman paper. Air bubbles were 
Material and Methods 
79 
removed and the blotting proceeded for 1 h at 20 V. Up to 4 gels were transferred at the 
same time. 
Afterwards the membrane was blocked in 5% milk powder (Saliter, Germany), 1% BSA 
in PBS-T for at least 1 h before cutting into up to 4 pieces for simultaneous detection of 
different-sized proteins. 
The membrane pieces were incubated with primary antibody in 5% milk powder, 1% 
BSA in PBS-T over night at 4 °C. An overview of all antibodies used and their respective 
dilutions is provided in table 7. After washing 3x 10 min with PBS-T, HRP-coupled 
(horseradish peroxidase) secondary antibody was applied diluted 1:5000 in 5% milk 
powder, 1% BSA in PBS-T and incubated for at least 1 h at RT. Before detection, the 
membrane was again washed 3x with PBS-T for 10 min. Enhanced chemiluminescence 
(ECL) was used to detect antibody signals. After incubation for 1 min with ECL™ Prime 
Peroxide Solution (Amersham) or SuperSignal West Pico Luminol/Enhancer Solution 
(Thermo Fisher Scientific) depending on antibody signal intensity, images were 
acquired using the Fusion SL Detection System (Vilber Lourmat, Eberhardzell, 
Germany). 
 
Table 7: Antibodies 
Antibody Supplier Species Dilution 
anti-16E6 Arbor Vita Corporation, USA, #849 mouse 1:2000 
anti-16E7 
kind gift of Martin Müller, DKFZ 
Heidelberg, clone NM2 
mouse 1:1000 
anti-18E6 Arbor Vita Corporation, USA, #399 mouse 1:2000 
anti-18E7 
H. Zentgraf, DKFZ Heidelberg, ID: B(28) 
#47 31.10-11.11.95 
chicken 1:1000 
anti-β-actin Sigma Aldrich, A2228 mouse 1:50000 in PBS-T 
anti-CKS1 Invitrogen, 36-6800 rabbit 1:250 
anti-FOXM1 Santa Cruz, sc-502 rabbit 1:500 
anti-p27 BD Transduction Laboratories, 610242 mouse 1:500 
anti-p53 (DO-1) Santa Cruz, sc-126 mouse 1:1000 
anti-p53 (FL393) Santa Cruz, sc-6243 rabbit 1:200 
anti-γ-tubulin Sigma Aldrich, T6557 mouse 1:5000 
anti-vinculin Santa Cruz, sc-73614 mouse 1:4000 
Secondary antibodies 
anti-chicken IgG-HRP Santa Cruz, sc-2428 goat 1:5000 
anti-mouse IgG-HRP Santa Cruz, sc-2005 goat 1:5000 
anti-rabbit IgG-HRP Santa Cruz, sc-2004 goat 1:5000 
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4.4 DNA-based methods 
4.4.1 Plasmid preparation 
Lysogeny Broth (LB) medium 
1% Bacto trypton 
0.5% yeast extract 
170 mM NaCl 
pH 7.0 
 
Solution I 
50 mM glucose 
25 mM Tris 
10 mM EDTA 
pH 6.7 
 
Solution II 
0.2 M NaOH 
1% SDS 
prepared freshly before use 
 
Solution III 
3 M potassium acetate 
11.5% acetic acid 
 
TE buffer 
10 mM Tris 
1 mM EDTA 
pH 8.0 
 
Plasmid isolation of small volumes (from 2-4 mL overnight bacterial culture in 
antiobiotic-supplemented LB medium) was performed using the PureLink™ Quick 
Plasmid Miniprep Kit (Invitrogen, Germany). For medium amounts of plasmid DNA 
(from 50 mL LB medium) the PureLink™ HiPure Plasmid Filter Midiprep Kit (Invitrogen) 
was used. Both kits were utilized according to the manufacturer’s instructions.  
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For purification of larger amounts of plasmid DNA the maxipreparation protocol based 
on Sambrook and Russell [224] was employed. To that end, 250 mL overnight culture of 
transformed bacteria was pelleted, resuspended in 10 mL solution I, lysed in 20 mL 
freshly prepared solution II and neutralized with 15 mL solution III. After briefly chilling 
on ice, lysate was centrifuged at 5500 x g and 4 °C for 10 min to pellet cellular debris. 
The plasmid-containing supernatant was transferred to a fresh tube and equal volume of 
isopropanol was added to precipitate DNA. After incubation for 30 min on ice, plasmid 
DNA was pelleted at 5500 x g and 4°C for 25 min. The pellet was dissolved in 4 mL TE 
buffer and 4 mL 5 M LiCl solution was added. After incubation for 30-60 min on ice and 
centrifugation at 5000 x g, 5 min, 4 °C, the supernatant was transferred to a fresh falcon 
tube and precipitated using EtOH. The resulting pellet was resuspended in 4 mL TE 
buffer with 4.4 g CsCl and supplemented with 100 μL ethidium bromide solution 
(10 mg/mL). Samples were transferred to 6 ml PA Ultraclimp tubes (Sorvall, Asheville, 
USA). Ultracentrifugation was then carried out at 220000 x g at 20 °C for 16 h in an 
OTD75B Sorvall Ultracentrifuge. The supercoiled plasmid DNA, visible through 
incorporation of ethidium bromide, was extracted and transferred to a 50 mL falcon 
tube. To remove ethidium bromide from plasmid DNA, extraction with water-saturated 
1-butanol was performed several times. Precipitation of plasmid DNA was then carried 
out by adding 2 volumes of ethanol and incubating at -20 °C for 1 h. Following 
centrifugation at 5500 x g and 4 °C for 30 min, DNA was resuspended in 4 mL TE buffer 
supplemented with 160 μL  5 M NaCl solution. DNA was again precipitated with EtOH 
and pelleted by centrifugation. Purified plasmid DNA was finally resuspended in 
200-500 μL TE buffer and concentration was determined with the NanoDrop ND-1000 
spectrophotometer (Peqlab, Erlangen, Germany). 
 
4.4.2 Cloning of shRNAs 
10x TNE buffer 
100 mM Tris, pH 7.5 
1 M NaCl 
10 mM EDTA 
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Electrophoresis buffer 
40 mM Tris 
5 mM sodium acetate 
1 mM EDTA 
pH 7.8 
 
6x DNA loading dye 
0.25% bromophenol blue 
0.25% xylene cyanol 
30% glycerol 
 
Oligonucleotides containing the target gene-specific shRNA sequence were ordered from 
Sigma Aldrich. Sense and antisense oligonucleotides were annealed using 2.5 µL each in 
50 µL total volume in TNE buffer, by heating to 95 °C for 5 min, transferring to 70 °C for 
10 min and slowly letting cool down the reaction mix to ca. 40 °C in a water bath. The 
annealed oligonucleotide was then kinase-treated in PNK A-buffer using the PNK 
enzyme (Thermo Scientific), by incubating at 37 °C for 30 min, then heating to 70 °C for 
10 min and letting cool down slowly to ca. 40 °C.  
It was then ligated into the BglII- and HindIII-digested and 5’-dephosphorylated pSUPER 
backbone, using the T4 DNA ligase in the appropriate buffer (Thermo Scientific) and 
incubating for 2 h at 21 °C. The ligase was then heat-inactivated at 65 °C for 5 min to 
terminate the reaction. 
Subsequently, competent Escherichia coli TG2 were transformed with the ligation mix 
using heat-shock transformation. To this end, E. coli TG2 were slowly thawed on ice. 
100 µL of competent bacteria were inoculated with 10 µL of ligation mix and kept on ice 
for 30 min. Heat shock was performed in a water bath at 42 °C for 45-60 sec. Afterwards, 
bacteria were transferred back on ice for another 10 min, before adding 750 µL of LB 
medium and shaking at 37 °C for 45-60 min. 10-50% of the transformed bacteria were 
then plated on an ampicillin-containing LB-agar-plate (1.5% agar agar for bacteriology 
(Gerbu, Heidelberg, Germany); 100 µg/mL ampicillin) and grown at 37 °C overnight to 
form clones. 
The next day, overnight cultures for “miniprep” were inoculated from single colonies, 
and the plasmids purified the day after (see 4.4.1). To check for correct insertion of the 
shRNA-containing oligonucleotide, restriction digest using EcoRI and HindIII 
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endonucleases (NEB) was carried out for 2 h at 37 °C. The appropriate amount of 6x 
DNA loading dye was added to the samples for analysis of the resulting fragment using 
agarose gel electrophoresis. This was performed in a 2% agarose gel stained with 
PeqGREEN non-toxic DNA/RNA dye (1:20000, Peqlab, Germany), run at 80-100 V for 
30-90 min in electrophoresis buffer. As a size marker, 5 µL SmartLadder (Eurogentec, 
Belgium) was used. DNA was visualized via UV transillumination in a gel documentation 
system (Intas Science Imaging Instruments, Göttingen, Germany). 
If positive in the restriction digest, plasmids were sent for verification by sequencing to 
Eurofins Genomics, Ebersberg, Germany. Analysis of the sequences was performed using 
the Basic Local Alignment Search Tool (BLAST) provided by the National Center for 
Biotechnology Information. After purification of correct plasmids by “midiprep” 
procedure, the sequences were tested for effective knockdown of their target gene. 
If shRNAs were intended for use in colony formation assays, they were cloned from 
pSUPER into a pCEP4 vector backbone to enable stable episomal plasmid maintenance 
via HYG selection. To this end, the respective pSUPER construct was digested with 
BamHI and XhoI restriction endonucleases (NEB), releasing the H1 promoter-shRNA 
fragment. After size separation using agarose gelelectrophoresis, the respective 
fragment was cut from the gel and extracted using the QIAquick Gel Extraction Kit 
(Qiagen, Hilden, Germany) according to the instructions provided by the manufacturer. 
The purified DNA fragment was ligated into open pCEP4 vector backbone (generated by 
restriction digest with BglII and XhoI, 5’-dephosphorylated, thereby removing the pCMV 
promoter), and transformed via heat shock into E. coli TG2. Positive clones were verified 
by restriction digest with SalI (NEB). 
 
4.4.3 Cloning of the CKS1B promoter construct pBL-CKS1B 
The human CKS1B promoter was cloned into the pBL luciferase reporter construct to 
study transcriptional regulation of the promoter via luciferase assays. To that end, a 
550 bp stretch located directly upstream of the first amino acid-coding ATG of CKS1B 
was amplified from HeLa genomic DNA by polymerase chain reaction (PCR). Primers 
were designed to add restriction sites for NotI (forward) and HindIII (reverse) to the 
amplicon. Primer sequences are given in table 9. The PCR reaction mix contained 
25 pmol of each primer, 250 ng of genomic DNA, 2.5 mM of each dNTP, and 5 U Pfu 
polymerase in the appropriate buffer. The PCR program is listed in table 9 and was 
carried out in the PTC-200 Peltier Thermal Cycler (MJ Research). 
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After verification of the correct size on a 1% agarose gel, the amplified DNA was 
digested with NotI and HindIII at 37 °C over night. Empty pBL backbone was opened by 
NotI- and HindIII-digestion and 5’-dephosphorylated. The CKS1B promoter construct 
was ligated into pBL using a vector:insert ratio of 1:5. The ligation was carried out using 
T4 DNA ligase and proceeded for 2 h at 21 °C. The ligation mix was transformed into 
E. coli TG2, positive clones were verified by NotI/HindIII test digest and sequencing. 
 
4.4.4 Cloning of FOXM1 promoter construct into pBL 
The ca. 330 bp FOXM1 promoter construct was amplified from pGL3-FOXM1 for cloning 
into the pBL luciferase reporter construct. The PCR reaction mix contained 25 pmol of 
each primer, 10 ng of pGL3-FOXM1, 2.5 mM of each dNTP, and 5 U Pfu polymerase in the 
appropriate buffer. The primers were designed to add restriction sites for NotI 
(forward) and HindIII (reverse) to the amplicon. Primer sequences are given in table 8. 
The PCR program is listed in table 9 and was carried out in the PTC-200 Peltier Thermal 
Cycler (MJ Research). 
After verification of the correct size on a 1% agarose gel, the DNA fragment was 
extracted from the gel and digested with NotI and HindIII at 37 °C over night. Empty pBL 
backbone was opened by NotI- and HindIII-digestion and 5’-dephosphorylated. The 
FOXM1 promoter construct was ligated into pBL using a vector:insert ratio of 1:5. The 
ligation was carried out using T4 DNA ligase and proceeded for 2 h at 21 °C. The ligation 
mix was transformed into E. coli TG2, positive clones were verified by NotI/HindIII test 
digest and sequencing. 
 
Table 8: PCR primers 
Name Sequence (5’ -> 3’) 
CKS1B fw (NotI) AATAAGCGGCCGCGGGTTCCGGGGTGAAAGAGTG 
CKS1B rev (HindIII) ATTAAGCTTATCGCTCGGTTTGCTAGCCTT 
FOXM1 fw (NotI) AATAAGCGGCCGCCCAGGGACCCGGGCCT 
FOXM1 rev (HindIII) TTGAAGCTTGGATCCCGGGAGGGAGG 
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Table 9: PCR programs 
 
 
 
 
 
 
 
4.5 RNA-based methods 
4.5.1 RNA extraction 
Isolation of total RNA was performed using the column-based PureLink RNA Mini Kit 
(Invitrogen, Germany) according to the manufacturer’s instructions. Cells were washed 
once with PBS and RNA lysis buffer freshly supplemented with β-mercaptoethanol was 
added directly onto the cells. When protein and RNA were extracted from the same 6 cm 
dish, cells were scraped from the dish in PBS using a plastic cell scraper and the 
resulting cell suspension was divided into two separate tubes.  The cells designated for 
RNA extraction were pelleted at 16100 x g, 10 sec, 4 °C, PBS was removed and RNA lysis 
buffer including β-mercaptoethanol was added. The lysate was resuspended and either 
stored at -20 °C or directly further processed for RNA extraction following the kit 
manual. To remove unwanted DNA from the samples PureLink DNase Set (Invitrogen) 
was applied. The purified RNA was eluted in 40-80 μl RNAse-free H2O and concentration 
was determined with the NanoDrop ND-1000 spectrophotometer (Peqlab). Purified RNA 
was stored at -80 °C. 
 
4.5.2 cDNA generation by reverse transcription 
The ProtoScript® II First Strand cDNA Synthesis Kit (NEB, USA) was used for cDNA 
generation. 500 ng total RNA per sample were transcribed in a total reaction volume of 
10 µL using oligo-dT primers. RNA mixed with primers was heated to 70 °C for 5 min in 
a PTC-200 Peltier Thermal Cycler (MJ Research) and cooled down to 4 °C before 
addition of buffer and enzyme. The reaction then proceeded for 5 min at 25 °C, was 
incubated at 42 °C for 1 h and finally heated to 80 °C for 5 min. The resulting cDNA was 
diluted by addition of 40 µL nuclease-free H2O and kept at -20 °C for long-term storage. 
 
CKS1B 
95 °C 2 min  
95 °C 1 min 
30x 58 °C 30 sec 
72 °C 1:50 min 
72 °C 5 min  
FOXM1 
95 °C 2 min  
95 °C 30 sec 
30x 58 °C 30 sec 
72 °C 1 min 
72 °C 5 min  
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4.5.3 Quantitative real-time PCR (qRT-PCR) 
qRT-PCR allows the quantification of cellular mRNAs after their reverse transcription to 
cDNA (see 4.5.2). Table 11 contains all primers used for qRT-PCR in this project. Prior to 
use, all primer pairs were checked for binding efficiency (80-110%) by generating a 
standard curve using serial dilutions. 
The reaction mix per sample contained 10 μl SYBRTM Green PCR Master Mix (Applied 
Biosystems, USA), 0.4 μl each of forward and reverse primer, 7.2 μl nuclease-free H2O 
and 2 µL cDNA. All reactions were run as duplicates. Final primer concentration was 
100 nM per primer per reaction. A water control without cDNA was used as negative 
control. The reaction was run in a MicroAmpTM Optical 96-Well Reaction Plate (Life 
Technologies, Germany) on a 7300 Real Time PCR System (Applied Biosystems, 
Invitrogen) according to the following program: 
 
Table 10: qRT-PCR program 
 
 
 
 
 
 
 
 
The generation of dissociation curves allowed detection of unspecific amplification 
artefacts. Calculation of mRNA expression was performed according to the comparative 
Ct (2ΔΔCt) method [225] with normalization to β-actin expression as internal reference. 
 
 
 
 
 
 
 
 
 
Inititation 50 °C 2 min  
Polymerase activation 95 °C 10 min  
Denaturation 95 °C 15 sec 
40x 
Annealing and elongation 60 °C 1 min 
Dissociation curves 
95 °C 15 sec  
60 °C 1 min  
95 °C 15 sec  
60 °C 15 sec  
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Table 11: List of qRT-PCR primers 
Primer Sequence (5’ -> 3’) Alternative name 
β-actin fw GGACTTCGAGCAAGAGATGGC  
β-actin rev GCAGTGATCTCCTTCTGCATC  
CKS1B fw2 TCGGACAAATACGACGACGAG  
CKS1B rev2 AACAGCAAGATGTGAGGTTCGGT  
FOXM1 fw1 GGCAGCAGGCTGCACTATC  
FOXM1 rev1 TCGAAGGCTCCTCAACCTTAAC  
HPV16 E6 fw3 AGCAATACAACAAACCGTTGTGT  
HPV16 E6 rev2 CCGGTCCACCGACCCCTTAT  
HPV16 E6/E7 fw CAATGTTTCAGGACCCACAGG HPV16 E6all fw 
HPV16 E6/E7 rev CTCACGTCGCAGTAACTGTTG HPV16 E6all rev 
HPV18 E6 fw1 AGACAGTATACCCCATGCTGCAT  
HPV18 E6 rev1 TCCAATGTGTCTCCATACACAGA  
HPV18 E6/E7 fw ATGCATGGACCTAAGGCAAC  
HPV18 E6/E7 rev AGGTCGTCTGCTGAGCTTTC  
 
HPV16 and HPV18 E6/E7 primers recognize all three transcript classes of HPV16 and 
HPV18 E6/E7. 
 
 
4.6 Statistical analysis 
If not indicated otherwise in the figure legends, all experiments were conducted at least 
three times with consistent results and one representative replicate is presented. 
Mean values and standard deviations were calculated using Microsoft Excel (Microsoft 
Office 2010) or SigmaPlot Version 13. Analyses of fold change values were carried out 
following logarithmic transformation. Statistical significance was determined by one-
way ANOVA using SigmaPlot software. P-values of ≤0.05 (*), ≤0.01 (**), or ≤0.001 (***) 
were considered statistically significant. 
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Supplemental figures 
 
Supplemental figure 1 (supplemental to figure 10): FOXM1 knockdown in SiHa only 
marginally alters cell cycle distribution and does not induce senescence. A: Cell cycle 
analyses of SiHa cells after FOXM1 knockdown. Cell cycle phase distributions are given in %. B: 
SA β-Gal assay of SiHa cells after FOXM1 knockdown. Split ratio: 1:10. A, B: Shown is one 
representative replicate of 2 independent experiments. siContr-1: control siRNA. 
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Supplemental figure 2 (supplemental to figure 13): FOXM1 knockdown by siRNA is 
effective over 120 h. HeLa (A), HeLa “p53 null” (B) and CaSki (C) were subjected to FOXM1 
knockdown. FOXM1 protein levels were monitored over 120 h. γ-tubulin: loading control. 
siContr-1: control siRNA. Data produced jointly with Julia Botta. 
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List of plasmids 
Table 12 
Plasmid shRNA target sequence (5’->3’) Source Comments 
pBCH - [226]  
pBCH-16E6 - [226]  
pBL - [126]  
pBL-CKS1B - see 4.4.3  
pBL-FOXM1 - see 4.4.4  
pCEP4 empty vector Invitrogen  
pCEP-shCKS1_1 GGACATAGCCAAGCTGGTC 
see 4.4.2 
 
pCEP-shCKS1_2 AAACTCAGATGCTTCCTCC  
pCEP-shCKS1_3 TGGTGACTTGCGGATTTAT  
pCEP-shFOXM1_1 GGACCACTTTCCCTACTTTTT  
pCEP-shFOXM1_2 AACATCAGAGGAGGAACCTAA  
pCEP-shFOXM1_3 TGGGATCAAGATTATTAACCA  
pCEP-shNeg TACGACCGGTCTATCGTAG [137]  
pCMV-16E7-HA/flag - [227]  
pCMV-16E7ΔDLYC-
HA/flag 
- 
[228]  
pCMV-E2F1 - 
Addgene 
#21667 
 
pCMV-Gal - [229]  
pCMV-HA/flag - [228]  
pCMVtk - [230]  
pCMVtk-p53 - [230]  
pGL3 basic - Promega  
pGL3-FOXM1 - 
[42] nucleotides -296 
to +60 
pGL3-FOXM1long - 
[42] nucleotides -2436 
to +60; GenBank 
Accession No. 
Y12337 
pGUP.PA.8 - [124]   
pGUP.PA.8-
p53CONLuc 
- 
[124]  
pSUPER empty vector [231]  
pSUPER-sh18E6/E7 CCACAACGTCACACAATGT 
[137] 
used as pSUPER 
sh18E6/E7 
pSUPER-sh18E6/E7-
563 
CAGAGAAACACAAGTATAA 
pSUPER-sh18E6/E7-
846 
TCCAGCAGCTGTTTCTGAA 
pSUPER-sh18E6-340 GACATTATTCAGACTCTGT 
used as pSUPER 
sh18E6 
pSUPER-sh18E6-349 CAGACTCTGTGTATGGAGA 
pSUPER-sh18E6-353 CTCTGTGTATGGAGACACA 
pSUPER-shCKS1_1 GGACATAGCCAAGCTGGTC [232], see 4.4.2  
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pSUPER-shCKS1_2 AAACTCAGATGCTTCCTCC [233], see 4.4.2  
pSUPER-shCKS1_3 TGGTGACTTGCGGATTTAT [234], see 4.4.2  
pSUPER-shContr-1 CAGTCGCGTTTGCGACTGG [235]  
pSUPER-shFOXM1_1 GGACCACTTTCCCTACTTTTT [43], see 4.4.2  
pSUPER-shFOXM1_2 AACATCAGAGGAGGAACCTAA 
[51], see 4.4.2 
used as pSUPER 
shFOXM1 pool pSUPER-shFOXM1_3 TGGGATCAAGATTATTAACCA 
pSUPER-shp53 GACTCCAGTGGTAATCTAC [231]  
p21Luc - 
[236] also referred to as 
pWWP 
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Abbreviations 
 
a. o. and others 
ANOVA Analysis Of Variance 
APS Ammonium Persulfate 
ATP Adenosine Triphosphate 
BER Base Excision Repair 
BLAST Basic Local Alignment Search Tool 
bp base pair 
BRCA2 Breast Cancer-Associated Protein 2 
BRIP1 BRCA1-Interacting Protein C-terminal Helicase 1 
C1 Compound 1 
ca. circa 
CBP Creb-Binding Protein 
CDDP cis-Diamminedichloridoplatinum, Cisplatin 
CDK Cyclin-Dependent Kinase 
cDNA Copy DNA 
CFA Colony Formation Assay 
CHR Cell Cycle Homologous Region 
CIN Cervical Intraepithelial Neoplasia 
CIN25 Chromosomal Instability Signature 25 
CKS1 Cyclin-dependent Kinases Regulatory Subunit 1B 
CPT Camptothecin 
DAPI 4’,6-Diamidino-2-phenylindole 
DDR DNA Damage Response 
dH2O Desalted Water 
Dlg Disks Large Homolog 
DMEM Dulbecco’s Modified Eagle’s Medium 
DMF Dimethylformamide 
DMSO Dimethyl Sulfoxide 
DNA Desoxyribonucleic Acid 
dNDP Desoxynucleoside Diphosphate 
dNTP Desoxynucleoside Triphosphate 
DOX Doxorubicin 
DREAM DP, Rb-like, E2F4 and MuvB 
DSB Double Strand Break 
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DTT Dithiothreitol 
E6-AP E6-Associated Protein 
E6-BP E6-Binding Protein (Reticulocalbin-2) 
ECL Enhanced Chemiluminescence 
EDTA Ethylenediaminetetraacetic Acid 
EdU 5-Ethynyl-2´-deoxyuridine 
EGTA Ethylene Glycol Tetraacetic Acid 
et al et alii (and others) 
EtOH Ethanol 
EXO1 Exonuclease 1 
FCS Fetal Calf Serum 
fig. Figure 
FOXM1 Forkhead Box Protein M1 
fw forward 
H2B Histone 2B 
HNSCC Head and Neck Squamous Cell Carcinoma 
HPV Human Papillomavirus 
HR Homologous Recombination 
HRP Horseradish Peroxidase 
HSP70 Heat Shock Protein 70 kDa 
hTERT Human Telomerase Reverse Transcriptase 
HU Hydroxyurea 
HYG Hygromycin B 
kbp kilo base pairs 
LB Lysogeny Broth 
log10 decimal logarithm 
MAGI Membrane-Associated Guanylate Kinase 
MEF Mouse Embryonic Fibroblasts 
MeOH Methanol 
MMB B-Myb-MuvB 
MMP-2/-9 Matrix Metalloproteinase-2/-9 
mRNA messenger RNA 
MuvB Multi-vulval Class B 
NBS1 Nijmegen Breakage Syndrome Protein 1 
NDP Nucleoside Diphosphate 
NER Nucleotide Excision Repair 
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NHEJ Non-Homologous End Joining 
NOK Normal Oral Keratinocyte 
NSCLC Non-Small Cell Lung Cancer 
ORF Open Reading Frame 
PAGE Polyacrylamide Gel Electrophoresis 
PBS Phosphate-Buffered Saline 
PCR Polymerase Chain Reaction 
PDZ Post synaptic density protein (PSD95), Disks large homologue (Dlg1) and 
Zonula occludens-1 protein (zo-1) 
PI Propidium Iodide 
PIPES Piperazine-N,N′-bis(2-ethanesulfonic acid) 
pRb Retinoblastoma-associated Protein 
PSG Penicillin, Streptomycin, Glutamine 
rev reverse 
RISC RNA-induced Silencing Complex 
RLU Relative Luciferase Unit 
RNA Ribonucleic Acid 
RNAi RNA Interference 
RT Room Temperature 
RT-qPCR Reverse Transcriptase Quantitative PCR 
SA-β-Gal Senescence-Associated β-Galactosidase 
SCF Skp1, Cullin1 and F-box protein 
SDS Sodium Dodecyl Sulfate 
Ser Serine 
shRNA Short Hairpin RNA 
siRNA Small Interfering RNA 
Skp2 S-phase Kinase-associated Protein 2 
SUMO Small Ubiquitin-related Modifier 
TEMED Tetramethylethylenediamine 
TUNEL Terminal Deoxynucleotidyl Transferase dUTP Nick End Labelling 
VEGF Vascular Endothelial Growth Factor 
XRCC1 X-ray Cross-Complementing Protein 1 
γ-H2AX phosphorylated Histone 2AX (Ser139) 
 
 
The one-letter code for nucleotides was applied according to declarations by the 
International Union of Pure and Applied Chemistry (IUPAC). 
Units  
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Units 
 
°C  degree Celsius 
Da  Dalton 
g   gram 
h   hour 
L   liter 
m  meter 
M   molar (mole/L) 
min   minute 
mol  mole 
sec   second 
U  enzyme unit 
V   volt 
x g  centrifugal acceleration 
%   percent 
 
Prefixes 
 
Symbol  Prefix   Factor 
k   kilo   103 
c   centi   10-2 
m   milli   10-3 
μ   micro   10-6 
n   nano   10-9  
p  pico  10-12  
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